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Loss of function mutation in CD11b has been associated with incidence of systemic lupus 
erythematosus (SLE), a disease driven by B cell production of pathogenic autoimmune 
antibody. Our previous work has revealed the ability of CD11b to regulate B cell receptor 
(BCR) signaling and control autoimmune disease in mice. However, how CD11b 
regulates the immune response under normal conditions remains unknown. Through the 
use of a CD11b knockout model, we demonstrated that CD11b-deficient mice have an 
elevated antigen-specific humoral response in a Th2 type immunization. Deletion of 
CD11b resulted in elevated serum IgM and IgG antibody, increases in antigen-specific 
germinal center (GC) B cells and plasma cells (PCs), and increased expression of survival 
and regulatory factors Bcl-XL and Blimp1 within these subsets. Subsequent experiments 
using a tissue-specific CD11b deletion model revealed this effect to be B cell intrinsic, 
and not altered by myeloid cell CD11b expression. Examination of BCR signaling in GC 
B cells of CD11b knockouts revealed defects in association of negative regulators SHP-1 
and pLyn with the BCR following stimulation, as well as alterations in nuclear 
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localization of GC regulators cMyc and FOXO1. Through the use of a CD11b-reporter 
mouse model, we identified multiple novel CD11b-expressing B cell subsets that are 
dynamically altered during immunization and autoimmune conditions. Lastly, we 
investigated the incidence of CD11b mutation rs1143679 in SLE patients and examined 
its effect on the clinical outcome of disease and impact on B cell function. These studies 
describe a novel role for CD11b in regulation of the healthy humoral response at the GC 
stage and reveal previously unknown populations of CD11b expressing B cell subsets, 
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 Maintaining an effective defense from outside harm is crucial to an organism’s 
survival, at both the macro and micro level. Infection from foreign bacteria, viruses, and 
other parasites all pose a deadly threat, but the mammalian immune system has evolved 
to combat these pathogens. 
Two major forms of immunity function to combat these dangers are; innate and 
adaptive immunity (1). The innate immune system is characterized by cells which initiate 
a response based on a non-variable, germ-line encoded receptor that recognizes broad 
pathogen-associated molecular patterns (PAMPs) (2). The adaptive arm of the immune 
system is comprised of cells which contain highly specific receptors generated through 
somatic recombination of the germ-line, and are able to produce immune memory; 
allowing a greater, more rapid, and more effective response upon repeated encounter with 
a given antigen (3). 
The adaptive compartment is composed of two broad cell types: T cells and B 
cells. The T cell compartment is largely considered to propagate cell-mediated immunity; 
driving elimination of pathogenic antigen by direct cell-to-cell contact and recognition 
via the T-cell receptor (TCR) (4). Conversely, B cells are mediators of humoral 
immunity. Not requiring direct cell contact with the B cell receptor (BCR), B cells secrete 
antibodies which are able to bind their cognate antigen at sites distal from the B cell 
itself. This binding action assists in pathogen elimination by activation of the 
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complement system, enhancing recognition of the foreign body by innate cells, and 
modulating the T cell response (5-7). 
 Activation of the B cell antibody response is a tightly regulated process. Inproper 
regulation can cause the production of antibody against self-antigens and lead to 
autoimmunity. Overzealous regulation would leave the B cell response inert, unable to 
effectively defend the body from foreign pathogen. An intricate network of signals and 
mechanisms act to maintain a healthy level of B cell response and strike a balance 
between necessary and unnecessary activation of B cells. In this work, we will discuss the 
role of cluster of differentiation 11b (CD11b) as a novel regulator of B cell activation in 
the normal B cell response, as well as its implications in autoimmunity. We will also 
investigate the impact of CD11b mutation on B cell function in systemic lupus 
erythematosus (SLE), a disease characterized by a severe pathogenic autoimmune B cell 
response. 
Regulation of B Cells and the Germinal Center Reaction 
 During development, B cells undergo random V(D)J gene recombination of the B 
cell receptor in order to produce a wide diversity of antigen specificities. The earliest B 
cell developmental stage to feature a functional, V(D)J rearranged Ig sequence is the 
immature B cell stage in the bone marrow. Even in healthy human subjects, 75% of the 
clones produced from this population were found to be autoreactive. This included major 
epitopes such as insulin, LPS, and nuclear antigens (8, 9). To eliminate the potential 
damage of these cells, several mechanisms exist to induce B cell tolerance, such as 
negative selection/deletion, induction of anergy, and re-editing of the BCR (10). Self-
reactive B cells may also escape central mechanisms of selection and appear in the 
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periphery, only to remain inactive even in the presence of self-antigen. These cells are 
classified as “ignorant” or “indifferent to self-antigens (11). Peripheral autoreactive B 
cells may also be regulated by selective differentiation into the marginal zone B cell 
compartment, which is more easily regulated by dependence on T cell interaction (12). 
The prevalence of these regulatory mechanisms at every B cell stage clearly indicates the 
importance of preventing the production and activation of autoreactive B cells.  
 B cells are able to sense nucleic acids via TLR7 and TLR9, which recognize RNA 
and DNA, respectively. The receptors, located intracellularly in the endosome, assist in 
the recognition of and response to microbes via detection of foreign nuclear antigen (13). 
However, they are also sensitive to self-nuclear antigen, and are involved in production 
of anti-nuclear antibodies (ANAs) (14). Cell death leads to release of complex nuclear 
antigens, such as Smith antigen/ribonucleoprotein (Sm/RNP) and nucleosomes. When 
autoreactive B cells specific for these epitopes encounter these free-floating antigens, 
they engage the BCR and are translocated to the endosomal compartment. Here, they can 
interact with TLR7 and TLR9, which serve as co-stimulatory signals to enhance the 
activation cascade which results in the B cell production of ANAs (15). Indeed, impaired 
TLR7 and TLR9 activity was shown to reduce production of autoantibody against 
Sm/RNP and DNA in mouse models of lupus, while enhanced TLR7 expression was able 
to induce lupus-like disease in healthy mice and accelerate pathogenesis in lupus-prone 
strains (16, 17). In humans, SNPs leading to increased TLR7 expression have been 
associated with SLE in certain populations (18). These findings demonstrate a necessity 
for control of B cell activation via the innate RNA and DNA-sensing pathway. 
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 Type-1 Interferons (IFN I) are responsible for activation signaling in the innate 
and adaptive immune system. These pathways control the presentation of antigen and 
production of cytokines vital to B cell activation. In B cells, IFN I also activates 
expression of BAFF, which is an essential cytokine for differentiation and development 
(19). Plasmacytoid dendritic cells (pDCs) are a major producer of IFN I, which then 
provides necessary activation signals for B cells. Overactivation of pDCs can lead to 
overproduction of IFN I and subsequently, overactivation of B cells (20). 
 The BCR signaling cascade is one of the major mechanisms for controlling B cell 
activation. Disruption of these mechanisms can lead to unwanted activation of the B cell 
response and potentially autoimmunity. A large cohort of SLE-associated genes are 
involved in this pathway, such as scaffold adaptor protein BANK1. BANK1 amplifies 
BCR signaling by linking the BCR-induced activation of Src-family kinases, including 
LYN, with PLCγ2 cascade IP3 and DAG calcium influx signaling (21). This mechanism 
then leads to further downstream activation of the PRKCB gene, which is also strongly 
associated with SLE (22). Indeed, recent mouse-model studies demonstrated BANK1-
deficient mice have decreased IgG production during autoimmune disease development 
(23). Another important player in the BCR pathway is RasGRP3. This protein amplifies 
Ras-mediated MAPK signaling and is involved in B cell antibody production and 
proliferation (24). It is also expressed in other cell types critical to the immune response, 
such as T cells and myeloid cells (25). Dysfunction of RasGRP3 in B cells can drive 
autoimmune activation in SLE and may contribute to disease progression via other cell 
types as well. 
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 The Src-family kinases LYN, BLK, and CSK serve as BCR inhibitory signals, 
and defects in these molecules have been linked to development of autoimmune disease. 
LYN-deficient mice have been shown in several models to develop B cell hyperactivity 
and autoimmunity (26). LYN enacts inhibition by recruitment and activation of inhibitory 
surface receptors FcGR2B and CD22. The cytoplasmic tail domains of molecules then 
recruit and activate SHIP and SHP-1 phosphatases which reduce the strength of the B cell 
activation signal (27). BLK is able to promote interaction between the aforementioned 
BANK1 and PLCγ2. Reduced BLK expression has been correlated with reduced 
frequency of marginal zone B cells and pre-B cells, however, these fewer marginal zone 
cells are hyper-responsive to BCR stimulation (28). BLK reduction also enhanced 
cytokine production and kidney disease in Faslpr lupus-prone mice (29). Lastly, CSK 
directly interacts with intracellular phosphatase LYP; which regulates activation of LYN. 
In SLE patients, overexpression of CSK has been associated with increased IgM 
autoantibody production and doubled frequency of transitional B cells. This CSK-LYP-
LYN mechanism affects SLE pathogenesis at multiple stages of B cell maturation (30, 
31). Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is associated with 
many autoimmune disorders, including SLE. Similar effects have also been confirmed in 
several mouse models (32, 33). In B cells as well as T cells, PTPN22 regulates CSK to 
control the BCR or T cell receptor (TCR) activation threshold (34). The interaction of 
PTPN22, LYN, BLK, and CSK in controlling BCR ligation signal is a crucial area of 
study for understanding the regulation of B cell activation. 
 Lipid phosphatase SHIP-1 and non-receptor tyrosine phosphatases SHP-1 and 
LYB/PEP are regulators of B cell tolerances, and have been implicated in autoimmune 
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disease (35). In mice, induced loss of SHIP-1 or SHP-1 caused a reversal of anergic state 
in nuclear-antigen reactive B cells, eventually leading to differentiation into plasma cells 
and high ANA production (35). Other studies have shown development of lupus-like 
disease in SHIP-1 or SHP-1 deficient mice (36, 37). These results not only elucidate 
SHIP-1 and SHP-1 as vital controllers of B cell activation, but also show the reversibility 
of anergy and the roles this process may play in autoimmune disease. 
 There are multiple co-receptors that inhibit B cell activation via recruitment of 
SHP-1, such as CD22, CD32B, and CD (35, 38). However, CD72 is uniquely specified in 
maintaining tolerance to nuclear antigens, making it a prime target for study in ANA-
dependent SLE. Additionally, polymorphisms in CD72 have been found to associate with 
SLE susceptibility (39). CD72 selectively binds Sm/RNP, and acts to inhibit activation 
signals when the BCR encounters and binds Sm/RNP antigen (40). This divalent binding 
of colocalized BCR and CD27 causes BCR-associated Lyn to phosphorylate the 
cytoplasmic tail of CD72, which in turn activates SHP-1 to suppress the BCR signal (41). 
In mice, deletion of CD72 causes severe lupus-like disease, even more drastically than 
disease caused in deletion of other inhibitory receptor CD22 (42). Interestingly, CD72 
does not repress BCR signal stimulated with polyclonal anti-IgM antibody, which further 
enforces the highly-specific function of this repressor in maintaining tolerance to 
Sm/RNP nuclear antigen (43). CD72’s high specificity also prevents it from binding 
microbial RNA, allowing it to “filter out” self-RNA from being sensed downstream by 
TLR7 (40). This finding implicates the possibility for other common auto-antigen 
restricted suppressive co-receptors in B cell signaling. 
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 Self-reactive and poly-reactive B cells that avoid negative selection and deletion 
may accumulate in the B-1 B cell fraction. B-1 cells tend to be polyreactive IgM or IgA 
class, and are able to form independent of T cell help via multivalent antigens such as 
LPS (44). This fraction can be further divided into B-1a and B-1b subsets. B-1a cells 
produce naturally occurring low affinity autoantibodies that are useful in the clearance of 
apoptosis-derived debris (45). The B-1b fraction generates IgM memory cells in response 
to T-independent antigen and has been shown to prevent certain secondary infections 
(46). The expansion of these B-1 cells has been correlated with autoimmune disorders, 
including SLE, in humans and mice (47). Deletion of SHP-1 in mice causes lupus-like 
disease and expansion of B-1 cells. However, deletion of Siglec-10, a SHP-1 recruiter 
expressed highly in B-1 cells, caused expansion of B-1 cells but only minor autoimmune 
symptoms. Though SHP-1 is an important regulator of B-1 cell expansion, their enhanced 
response in its absence is not potent enough to induce severe lupus-like autoimmunity 
alone (37, 48). This demonstrates the dynamic nature of B cell regulation, outlining the 
need for different levels of control depending on the specific subset’s function and 
potency. 
 Not all B cell subsets are activators of the humoral response. Regulatory B cells 
are able to suppress the function of T lymphocytes though multiple mechanisms, 
including IL-10 (49). This, in turn, is able to regulate the B cell activation via reduced T 
helper cell interaction, resulting in a reduced antibody response. Not limited to the 
adaptive arm, regulatory B cells can also inhibit  DCs, NK cells, and macrophages, which 
can contribute to an overall limited inflammatory response (50). Indeed, animals lacking 
IL-10 producing regulatory B cells develop more severe autoimmune disease, mediated 
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by several cell types (49). Interestingly, this regulatory subset is able to differentiate into 
antibody producing plasma cells after a brief period of IL-10 production, revealing a 
mechanism of transient regulation by B cells on their own response (51). 
The interaction between B cells and T cell is an important step in immune 
activation. B cells can serve as antigen presenting cells (APCs) by endocytosing 
autoantigens and presenting them mostly on MHC-II (52). Signaling via the MHC-II is 
heavily regulated by several associative molecules including CD19 and CD22 via SHP-1, 
drawing many parallels with BCR signal regulation (53). MHC-II genes HLA-DR2 and 
HLA-DR3 are strongly associated with SLE, though their exact role is not well 
understood (54). Co-stimulatory signals also play a large role in regulation of B cell 
activation. B cell OX40L interacts with OX40 (CD134) on T cells to enhance B cell 
proliferation and differentiation. In T-regulatory cells, this interaction negatively 
regulates generation of IL-10, which helps maintain tolerance (55). 
 The marginal zone (MZ) B cell compartment differentiates from transitional B 
cells; a brief stage of development following generation in the bone marrow but before 
maturity in the spleen. Named for their location in the marginal zone of the spleen, MZ B 
cells act as an early defense against T-independent blood-borne pathogens (56). They 
respond strongly to TLR activation and are able to quickly differentiate into plasma cells 
without the need for direct co-stimulation signals from T cells, instead using soluble 
signals and cytokine from DCs, neutrophils, and T cells (57). In humans, MZ B cells are 
present in the spleen and peripheral blood, but in mice they are restricted to the MZ of the 
spleen (58). Activation of MZ B cells is controlled by BCR, BAFF/BAFF-R, and Notch 
signaling. Their response is controlled by standard BCR negative regulatory mechanisms 
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such as SHP-1 and CD22 inhibition. MZ B cell expansion has been observed in multiple 
lupus mouse models and have also displayed increased generation of anti-dsDNA IgM 
antibody (59, 60). In humans however, the role of MZ B cells remains unclear. 
 Follicular (FO) B cells also derive from the transitional B cell stage. Unlike MZ B 
cells, FO B cells do require cognate T cell signaling help which causes them to be much 
slower to differentiate into effector plasma cells. Thus, their role in the T-independent is 
minimal (56). However, they are the major source of the T-dependent B cell reaction. FO 
B cells migrate between the splenic follicles, lymph nodes, and the circulation until they 
contact antigen. They may also encounter antigen presented by MZ B cells in the follicle 
(61). Upon activation, they migrate to the B-T border of the lymph node and spleen via 
CCR7 expression. Here they engage with T helper cells and receive proliferative signals. 
The specific of this interaction vary depending on the type of T helper cell (Th1, Th2, 
Th17, Tfh), which is dependent on T cell-DC interaction the antigen/pathogen molecular 
pattern (62). Following activation, FO B cells differentiate into extrafollicular plasma 
cells, or enter the germinal center reaction to increase antigen affinity (63). 
 To produce high amounts of effector antibody, including autoreactive epitopes, 
activated B cells differentiate into plasma cells. This process may happen either through 
the extrafollicular pathway, or though the germinal center (GC) reaction. Following 
engagement of mature B cells with cognate antigen, B cells migrate to the T-B follicle 
border in secondary lymphoid organs to receive CD4 T cell co-stimulatory signals. These 
signals drive rapid proliferation of the B cells which then locate to either the outer follicle 
pathway at the T-B border to become extrafollicular plasma cells (EF PCs), or to the 
central B cell follicle to initiate the germinal center. The exact mechanisms controlling 
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this divergence are still not fully understood, though some studies have suggested BCR 
affinity may be a factor under competitive conditions (63). 
 EF PCs produce a faster but lower affinity antibody response which is important 
in quickly responding to infection (64). These differentiating B cells increase expression 
of Blimp-1 (or PRDM1) as well as CXCR4 and CD138 (65). T-helper cells directly 
interact with the B cells and provide essential stimulatory signaling through CD40, ICOS, 
and IL-21 (66). This drives differentiation into EF PCs and class switch recombination 
(CSR) of the Ig heavy chain (63). These cells then chemotaxis via CXCR4 to the red pulp 
of the spleen and form EF foci. Here, higher affinity BCRs are selected to survive and 
proliferate. These newly formed EF PCs can then produce an antibody response and 
reside in peripheral lymphoid organs, as well as generate memory B cells (67, 68). EF 
PCs may play a role in autoimmunity due to their dependence on TLR9 signaling to 
migrate to the EF foci, which would encourage differentiation of DNA-reactive B cells 
(69). However, most research is focused on the GC pathway of PC differentiation rather 
than the shorter lived and lower affinity response of EF PCs. There are also no effective 
markers to distinguish EF PCs from GC PCs, making their effect hard to delineate in 
long-term responses (70). Recently, some animal studies have found enhanced EF PC 
differentiation in autoimmune models, and a possible large population of EF derived PCs 
in SLE patients (71). Though their role is less characterized in SLE, the EF PC 
population may play a role in disease progression and warrants further investigation. 
Cells that do not enter the EF pathway instead enter the GC reaction inside the 
central B cell follicle. Expression of transcription factor B cell lymphoma 6 (Bcl6), an 
essential and hallmark regular of the GC, begins at this time and continues for the 
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majority of the GC stage (72). Cells in the center may cluster together and interact with 
follicular dendritic cells (FDCs) to initiate the GC reaction (73, 74). FDCs present in 
these tissues help to organize B cells to initialize and form the GC structure, serve as 
antigen presenting cells, and propagate B cell survival and proliferation during the GC 
reaction (75, 76). Infection or immunization is required to initiate GC formation in 
healthy individuals, but lupus mouse models are able to spontaneously generate GCs, 
indicating an important role for this process in disease (77). 
The mature GC is defined by two distinct and polarized compartments; the light 
zone (LZ) and the dark zone (DZ). The DZ forms more closely to the bordering T cell 
follicle and contains very little supportive FDCs. Here, the B cells cluster and undergo 
rapid proliferation. These cells are hallmarked by expression of chemokine CXCR4 and 
activation-induced cytidine deaminase (AID)(AICDA), as well as near-constant activity 
of the G2 and M phases of proliferation(78) (78, 79). AID expression combined with 
high-error DNA polymerase drives B cell somatic hypermutation (SHM), which causes 
random rearrangement of the Ig that may possibly increase antigen affinity (80). Every 
round of division further increases the amount of mutations and thus the chance of 
increased (and perhaps decreased) affinity maturation. These DZ GC B cells will then 
migrate to the LZ to compete for selection with their newly re-arranged BCR. The 
highest affinity B cells will out-compete those of lower affinity and return to the DZ for 
further rounds of SHM and CSR. It has been demonstrated that many more cells move 
from the DZ to the LZ than from the LZ to the DZ, indicating that high amounts of 
selection are occurring in the LZ paradigm of this process (81). 
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The LZ forms close to the marginal zone and contains many FDCs, as well as 
non-participant naïve B cells (82, 83). FDCs present antigen to B cells via the Fcγ 
receptor and provide anti-apoptotic signal via BAFF and Notch ligands. These 
interactions are short-lived, lasting about 3 minutes (84, 85). This step serves a selector 
for high affinity BCRS, as lower affinity B cells will have weaker and more transient 
interactions with FDCs, depriving them of necessary anti-apoptotic signals. Defective 
negative regulation of the BCR at this step can allow for the survival of B cells that have 
weak binding or off-target specificity, including self-antigens. FDCs can also drive off-
target effects through the presentation of self-antigen for selection. Indeed, a study has 
identified the presence of nuclear antigens presented on FDCs on SLE patients (86). 
Some SLE patients also display disarray of the FDC network that associates with 
lymphadenopathy (87). These findings, supported by the essential role of FDCs in some 
mouse models of arthritis, suggest FDCs may play a part in regulation of the autoreactive 
B cell response (88). 
The LZ also contains T follicular helper (Tfh) cells, which provide crucial signals 
to B cells to regulate their size, restrict low affinity GC B cell entry into the reaction, 
provide support signals for high affinity GC B cells, and select for high-affinity B cell 
affinity maturation (89, 90). Like GC B cells, Tfh cells are also dependent on Bcl6 
expression during the GC reaction (72). Tfh engagement is vital as GC B cells cannot 
trigger BCR engagement and must depend on Tfh signaling to promote proliferation and 
survival. CD40L, IL-4, and IL-21 are the most critical signals provided by Tfh cells, 
though there are others (91). IL-4 and IL-21 promote class switching to IgG1, while 
CD40 is a vital co-activation signal of the BCR (92). These signals compete against Fas-
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FasL interactions that can lead to cell death, thereby serving as another layer of selection 
for higher-affinity BCRs (91). This Fas-FasL signaling is also important in the prevention 
of autoimmunity, as B cell depletion of Fas leads to lupus-like disease (93). Interestingly, 
the Tfh cells receive many inhibitory signals from GC B cells to prevent over 
proliferation due to constant engagement of the TCR. High PD-L1 expression on GC B 
serves not only to inhibit Tfh proliferation, but also reduces Tfh ICOS and IL-21 
expression, thereby self-regulating the amount of Tfh help the GC B cell receives (94). 
This intricate interaction with Tfh cells acts as a crucial regulatory step of the GC 
reaction, and its disruption may have pathogenic effects. Increased frequency of Tfh cells 
in the periphery has been associated with autoantibody-related diseases, including SLE 
(95). Indeed, clusters of Tfh and GC B cells are found in the kidneys of lupus nephritis 
patients, demonstrating a direct link to B cell regulation and pathogenesis (96). 
The GC reaction gives rise to both memory B cells and PCs. Lower affinity GC B 
cells differentiate into the memory subset, while higher affinity cells become PCs. 
Memory cells also arise from the GC much earlier than PCs (97, 98). IL-21 signaling also 
drives differentiation to PCs over memory B cells (99). At the transcriptional level, 
Bach2 has been shown to be important in memory B cell selection, while other 
transcription factors such as Blimp1 and IRF4 are tied to the PC fate (100, 101). PC 
differentiation is initiated in the LZ, but the cells then move towards the dark zone to 
complete their final rounds of proliferation as plasmablasts before exiting the GC into the 
red pulp (102). Proper regulation of these PC and memory B cell differentiation processes 




Newly differentiated PCs usually survive for a few weeks without further 
stimulation, decreasing by as much as 95% by 30-days post infection in some models 
(104). Memory B cells are traditionally considered the mediators of long-term humoral 
immunity, but s subset of long-lived PCs has also been identified. These cells have been 
found as late as 10 years post-vaccination and persist despite depletion of memory B cells 
(105, 106). Long-lived PCs contribute to the pathogenesis of lupus-like disease in mice 
and are unaffected by some traditional treatment methods (107, 108). The survival of 
both long and short-lived PCs is dependent on APRIL and BAFF-signaling and is 
enhanced by other signals such as IL-6 and CD28 (109-111). The prolonged survival of 
PCs in SLE is one cause for high autoantibody levels and subsequent tissue damage. 
Lupus mouse models show increased expression of APRIL, BAFF, and IL-6, and these 
trends can be found in human SLE patients as well (112, 113). Under normal conditions, 
limited amounts of PCs can be found in peripheral organs such as the spleen, bone 
marrow, and even kidney. In lupus mouse models, the amount of PCs in these sites is 
greatly increased, indicating an increase in PC support and survival signals in these 
tissues (114).  
PC tolerance is maintained through different mechanisms, depending on the 
source of the cells. EF PCs are tolerogenic in nature due to the short duration of their 
response, and the decreased affinity compared to GC PCs. Also, most EF PCs produce 
IgM class antibody rather than more potent and pathogenic IgG. In MRL-lpr lupus mice, 
the presence of IgM autoantibody was able to delay onset of disease, demonstrating a role 
for antibody class balance in maintenance of tolerance (115). 
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GC PCs are selected for tolerance in the GC phase. One proposed mechanism is 
through competition for T-helper or FDC survival signal. GC B cells which begin as or 
become self-reactive through SHM will be outcompeted for survival signaling by cells 
that remain on target for foreign antigen and either die or fail to differentiate (78). 
Though this mechanism would fail if T-helper or FDCs first bind and present self-
antigens, it does offer a layer of protection against autoimmune activation. Interestingly, 
the frequency of IgG class self-reactive memory B cells is much higher than IgG PCs, 
indicating a role of self-reactivity in determining GC B cells differentiation between these 
two subsets (116). Prolonged expression of MHC-II on GC PCs though the proliferative 
stage suggests another tolerance mechanism in the requirement for T cell interaction as 
they reach terminal differentiation (117). 
 Hyper responsiveness of B cells can result from ineffective regulation. Increased 
signaling in the BCR activation pathway following antigen binding cascades downstream 
to increase the B cell response. There are multiple signaling molecules and factors 
involved in this mechanism, many of which are established genetic risk alleles for SLE 
(118). This includes both increases of function for pro-signaling molecules such as 
BANK1 as well as decreased function for negative regulators of BCR signaling including 
LYN (119, 120). Non-BCR activation pathways, such as type-I IFN, can also contribute 
to hyperresponsiveness by decreasing the BCR signal threshold required to induce the B 
cell response (121). The hyperresponsiveness caused by these abnormalities can allow 
autoreactive B cells to circumvent affinity-based selection mechanisms in the LZ of the 
GC, leading to proliferation in the DZ and eventual production of PCs (122). TLR 
signaling also contributes to B cell activation. Increased TLR7 expression in mice has 
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been shown to spontaneously increase GC formation and plasmablast production leading 
to autoimmunity (123).  
All of these findings clearly outline a widespread and complex pathway of B cell 
development and regulation. Multiple mechanisms contribute to maintaining an 
appropriate level of B cell response. Dysfunction of these mechanisms can lead to 
overactivation and autoimmune disease. Not limited to the B cells alone; abnormalities in 
the various cells that support and interact with B cells can also drive this 
hyperresponsiveness. 
Classic Functions of CD11b  
CD11b is a surface-bound receptor classically associated with myeloid cells such 
as neutrophils and macrophages. An association of CD11b mutation with SLE incidence 
was identified several years ago, though much of its disease contribution was attributed to 
typical CD11b-expressing myeloid cells (124). However, the B cell centric nature of SLE 
begs the question; how does CD11b impact B cells in disease pathogenesis? Does it act 
indirectly via alterations in myeloid cell function, or do these mutations affect B cell 
function directly? A better understanding of the classic function of CD11b is necessary to 
approach this question. 
 CD11b is expressed on phagocytic cells, natural killer (NK) cells, and has also 
been found on small populations of T and B cells. It makes up the α subunit of the 
heterodimer Mac-1, also known as CR3 or integrin αMβ2 (ITGAM). The other half of the 
integrin, the β subunit, is CD18. Mac-1 is a member of the β2 integrin family expressed 
exclusively on leukocytes, which includes LFA-1, p150, and integrin αDβ2. The α 
portions of all family members are similar in both structure and function (125). 
17 
 
Mac-1/CR3 can act as a complement receptor, cellular adhesion molecule, and a 
transmembrane signaling adapter. In phagocytes and NK cells, it can bind ICAM-1 on 
endothelial cells to allow entry into sites of inflammation (126). The ability to bind 
complement is the source of its CR3 namesake. This mechanism is used in initiating 
phagocytosis of microorganisms, apoptotic cells, or cellular debris opsonized with iC3b 
or immune complexes (127). However, it is also capable of binding many other ligands 
and is regarded as loosely restricted. 
Mac-1 signaling is bi-directional, capable of both inside-out and outside-in 
pathways (128). Inside-out pathways are initiated via intracellular signaling from other 
nearby surface receptors like the TLRs, chemokine receptors, and the TCR. These induce 
conformational changes in Mac-1 that can alter its affinity for ligands. Outside-in 
signaling is initiated by direct binding of Mac-1 with extracellular ligands, before or after 
inside-out signaling has already taken place. These pathways are involved in 
phagocytosis, cellular adhesion, changes in gene expression, and other functions (129).  
 In DCs, Mac-1 can inhibit function at inflammatory sites that lack pathogenic 
signals. This downregulatory mechanism decreases DC expression of maturation marker 
CD86 to dampen their ability to stimulate T cell proliferation to reduce unwanted 
immune responses in a non-pathogen inflammatory event (130). Macrophage Mac-1 is 
able to negatively regulate low-avidity TLR inflammatory responses. In a negative-
feedback pathway, TLR-induced PI3-kinase activates CD11b to recruit Srk-family 
kinases that degrade signaling downstream of TLR, such as MyD88 and TRIF (131). 
Another macrophage function of Mac-1 is cross-regulation of heterologous receptor 
signaling. It can regulate type-I interferon and TLR4 signaling via Srk-family kinases that 
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act as inhibitors of downstream signaling while simultaneously inducing expression of 
anti-inflammatory cytokine IL-10 (132). Mac-1 acts as a negative regulator in NK cells as 
well. NKs greatly increase expression of CD11b upon maturity to keep unwanted 
activation in check. In an inducible hepatitis model, NK CD11b deficiency led to much 
more rapid and severe liver damage, thus demonstrating the pathogenic potential of these 
cells without CD11b regulation (133). 
Mac-1 is also important in establishing peripheral tolerance. CD11b-deficient 
mice challenged orally with antigen display an overproduction of IL-6 by APCs, leading 
to high differentiation of T cells into the Th17 subset. These Th17 cells then produce high 
amounts of IL-17 that interferes with the establishment of oral tolerance and causes 
exaggerated immune response to inert oral antigen (134). The systemic tolerogenic 
function of Mac-1 is supported by its effect in lupus mouse models. Faslpr mice develop 
much more severe disease when Mac-1 is deficient. Deletion of structurally similar and 
familiar integrin LFA-1 had the opposite effect of preventing lupus-like disease (135). 
Clearly, Mac-1 plays an inhibitory role across many cell types, and its function is tightly 
regulated and highly specific even when compared to highly similar molecules. 
CD11b Regulates B Cell Receptor Signaling 
 By convention, CD11b is considered a myeloid cell marker. However, the 
association of CD11b/ITGAM mutation with SLE, a disease driven by humoral 
autoimmunity, suggests a function in B cells as well. In 2013, our lab released a study 
identifying CD11b expression on B cells acting as a negative regulator of BCR signaling. 
This effectively demonstrated a role in controlling B cell autoimmunity and established 
the basis for the works of this dissertation (136). 
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 The known association of ITGAM mutations linked to SLE and the understudied 
function of CD11b in B cells led to this investigation. Initial experiments sought to 
identify CD11b expression on various B cell populations in anti-snRNP transgenic mice. 
Here, CD11b was observed in the developmental B cell stages in the bone marrow, 
follicular, marginal zone, B1a, and B1b B cells. This effectively established the presence 
of CD11b at all stages of B cells at different expression levels. 
 In the next phase of the study, the effect of CD11b-deficiency was examined 
using cells from CD11b global knockout mice. Splenic B cells were stimulated with anti-
IgM in vitro and it was found that CD11b KO cells hyper-proliferated compared to 
controls. Interestingly, stimulation with other signals including LPS and CpG did not 
result in differential proliferation, suggesting this is a BCR-pathway specific 
phenomenon. Cell viability was enhanced in CD11b deficient cells following IgM 
stimulation, indicating increased cell survival. Supporting this, cell survival genes were 
also more highly expressed in KO cells. These cells showed enhanced entry into the S 
and G2/M phases of the cell cycle compared to controls. These results outline a role in 
CD11b for surprising B cell proliferation in response to BCR pathway stimulation. 
 The impact of CD11b global deficiency was then examined in vivo. WT or 
CD11b KO mice were immunized with apoptotic cells, a major source of auto antigen in 
SLE. KO mice produced significantly more anti-snRNP antibody and ANAs than 
controls, as well as a higher frequency of antibody producing PCs. CD11b-deficient mice 
also had severe Ig deposition in the kidney while controls did not. Because these mice 
had global CD11b deletion, a chimera model was used to examine the impact of CD11b-
sufficiency in the B cell developmental stages in the bone marrow. Indeed, these mice 
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demonstrated the same autoreactive phenotype following immunization, indicating 
CD11b impacts autoimmunity after development. 
 Because CD11b is expressed on many cell types, an adoptive transfer into Rag1-
defecient mice was used to limit CD11b-knockout to B and T cells. Following apoptotic 
cell immunization, recipients of CD11b KO cells produced greater auto antibodies and 
had increased plasma cell frequency compared to controls. The survival of CD11b-KO 
transferred cells was also greater, correlating with earlier results. B cell deficient μMT 
mice were utilized in a similar experiment. Again, KO recipients had increased 
autoimmunity, suggesting a B intrinsic defect. 
 More in-depth signaling studies were then preformed to examine the mechanism 
behind CD11b’s effect on autoimmunity. Anti-IgM stimulated CD11b KO B cells had 
decreased levels of Lyn and CD22 phosphorylation. However, many other BCR-vital 
signaling proteins were unchanged. Calcium influx assay revealed increased calcium flux 
following BCR crosslinking, as well as increased calcium sensor STIM-1. These results 
suggest CD11b is involved in the BCR-Lyn-CD22 regulation circuit. 
 In order to produce a model more relevant to human disease, the next set of 
experiments used a CD11b-lacking B cell line transfected to express either functional 
human ITGAM or SNP variant rs1143679. Calcium influx on variant-expressing cells 
was increased compared to controls, mimicking the knockout phenotype seen in mice. 
Imagestream analyses were then used to examine the colocalization of major BCR 
signaling pathway players. Without stimulation, CD11b variant cell lines had 
significantly decreased colocalization of BCR with CD22 and SHP-1 signals but no 
change with p-Lyn. After BCR stimulation, variant cells had significantly less BCR 
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colocalization with p-Lyn. In both variant and WT expressing cells, CD11b dissociated 
from the BCR following stimulation. However, variant CD11b significantly decreased 
colocalization with CD22, p-Lyn, and SHP-1 following stimulation while WT cells did 
not. These findings demonstrate CD11b mutation impacts the ability of BCR-negative 
regulators to associate with the BCR. 
 Clearly, CD11b functions as a regulator of BCR signaling to impact B cell 
activation; however, the mechanisms behind this need to be more thoroughly 
investigated. We hypothesize that B cell intrinsic CD11b is able to regulate the healthy 
immune response and is not limited to control of autoimmune signaling. Additionally, 
CD11b functions as a BCR signaling regulator in multiple B cell subsets. We will address 
these unknowns by examining the impact global CD11b deficiency in non-autoimmune 
animals, specifically deleting CD11b in B cells in vivo, and surveying CD11b expression 
in various B cell populations under different immune settings. Lastly, we will study the 
impact of CD11b mutation in human SLE patients to determine its impact on B cell 
















 Stimulation of a naïve B cell by antigen can result in divergent outcomes. It may 
become activated and proliferate to generate an immune response, or it can mediate 
tolerance to the antigen by induction of apoptosis or anergy. The decision between these 
polar fates is controlled by a number of factors that include the strength of the signal that 
results from antigen binding of the BCR and the input of co-stimulatory signals that can 
inhibit or propagate activation. These events also determine the magnitude and longevity 
of the resulting humoral response. Regulation of these signals is crucial to maintain a 
healthy level of antibody response that is not excessive and potentially pathogenic or 
underwhelming and unable to effectively provide immunity against foreign agents. 
Our previous work has identified CD11b as a negative regulator of BCR signaling 
in autoimmune animals. The presence of this mechanism implies a function for regulation 
of the normal immune response as well. However, the autoimmune setting is highly 
irregular. Alterations to homeostasis and bias of an autoimmune genetic background can 
skew the normal function of this regulatory factor. In order to better understand the role 
of CD11b as a regulator of B cell activation, we must examine its effect in a normal, non-
autoimmune setting. 
BCR Activation Governs B Cell Fate 
The type of stimulation, dose, affinity, and duration of signal can all govern the 
fate and strength of the B cell response. Effective activation of the BCR is dependent 
upon a strong, continuous stimulation and the presence of co-stimulatory signals (137). 
Early stage division following activation is strongly linked to differentiation into class 
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switch antibody-producing cells. The magnitude of this critical early division is 
controlled by the duration and concentration of both T-dependent and innate TLR signals 
(138). Negative regulations of BCR signaling, which may include CD11b, act as 
gatekeepers during these vital steps and prevent weakly binding off-target antigens from 
eliciting a response. 
 The importance of BCR signaling is not limited to the activation of naïve B cells. 
Multiple stages of B cell development utilize the BCR to drive proliferation, selection, 
and survival (139). The GC reaction is vital to the production of an effective high affinity 
and long-term humoral response and is formed based on BCR signaling. B cells are 
recruited into the GC or the EF pathway based on affinity for antigen (140). Higher 
affinity results in more competitive binding to the BCR and subsequent antigen uptake. 
The increased activation signal from BCR ligation and increased antigen available for 
MCH presentation then drive higher duration T-B interactions which govern B cell fate 
(141). Within the GC, BCR signaling is largely dampened by high activity of SHP-1. 
This effect is believed to help drive selection via GC B cell dependence on FDC and Tfh 
help for survival (142). However, a small subset of light zone GC B cells have been 
found to have active BCR pathway activity (143). These cells may be actively engaging 
with FDCs to uptake antigen, triggering short-lived BCR pathway activation that is 
quickly smothered by enhanced negative regulatory signaling.  This BCR signaling 
within GC B cells, along with co-signals like CD40, can drive the expression of vital GC 
regulators FOXO1 and cMyc (144). FOXO1 regulates GC B selection, and its expression 
is required for maintaining the dark zone of the GC cycle (145). cMyc is essential for GC 
maintenance and initiation and limited to the light zone. It is most highly expressed 
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following GC B engagement with Tfh cells (146). This demonstrates the critical 
downstream effects of BCR signaling in driving an effective GC B cell response. 
Negative Regulation of BCR Signaling is Highly Specific 
Ligation of the BCR results in a cascade of downstream signaling events that 
contribute to activation of the B cell. This signaling pathway is negatively regulated 
though a system of multi-faceted inhibitors. At the cell surface, FcγRIIB, CD72, Siglec-
G, and CD22 co-receptors containing cytoplasmic immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) become phosphorylated via Lyn following BCR ligation (147). 
These phosphorylated regions are then able to recruit phosphatases, such as SHP-1, 
which can inactive phosphorylation signals downstream of the BCR including PIP3, and 
Syk (148, 149). These various surface co-receptors negatively regulate through different 
downstream effectors. CD22 acts mainly through SHP-1, while FcγRIIB can only recruit 
SHIP-1 (147). Indeed, each of these inhibitory co-receptors has been demonstrated to 
serve distinct regulatory functions.  CD72 recognizes self-antigen Sm/RNP, and acts as 
an autoimmune regulator (150). CD22 regulates the constantly low level activation of 
BCR known as tonic signaling, which serves to promote resting B cell survival (151). 
Similarly, Siglec-G maintains B-1 B cell homeostasis (152). Our previous study found 
that CD11b deficiency caused more severe disease in Sn/RNP autoimmune mice, 
possibly via defects in CD72. However, CD11b was also necessary to maintain 
association of CD22 and SHP-1 with the BCR upon stimulation, suggesting a role in 
controlling tonic signaling. These findings suggest a larger role for CD11b in controlling 




In the following experiments, we examine the effect of CD11b deficiency in a 
Th2 immunization setting to determine its function on B cells in the normal immune 
response. We found that a global loss of CD11b leads to an increased antibody response, 
as well as higher amounts of antigen-specific GC and PCs. In vitro examination of GC 
BCR signaling reveals defects in the SHP-1 and pLyn negative regulation pathway and 
altered utilization of critical GC regulatory factors FOXO1 and cMyc. These data 
describe a novel role for CD11b in regulating a healthy immune response, as well as 








NP Tg CD11b-/- knockout mice (NP KO) were generated by interbreeding CD11b global 
knockout mice with NP Tg mice (The Jackson Laboratory). CD11bloxp/loxp mice were 
generated for the purpose of this study using CRISPR/Cas9. Conditional knockout mice 
(cKO) were generated by interbreeding CD11bloxp/loxp with CD19-cre or Lyz2-cre (The 
Jackson Laboratory) mice to obtain CD19;cre-CD11bloxp/loxp and Lyz2-cre;CD11bloxp/loxp 
mice, respectively. Mice at 6–8 weeks of age with both sexes were used for immunization 
experiments. All mice were housed and bred in a conventional facility at the University 
of Louisville. Animal care and experiments were conducted in accordance with the 
National Institutes of Health guidelines and were approved by the Institutional Animal 
Care and Use Committee at the University of Louisville. 
 
Immunizations and Ab Detection 
NP tg or NP KO mice were immunized via i.p. injection of 50μg NP20-29-CGG in Alum 
adjuvant at a 1:1 ratio. Conditional knockout or control mice were immunized via 
intraperitoneal (i.p.) injection of 100μg OVA peptide or 50μg NP20-29-CGG (Biosearch 
Technologies) in Alum adjuvant at a 1:1 ratio. Anti-NP and anti-OVA and antibody titers 
were measured via enzyme-linked immunosorbent assay (ELISA) using a 96-well plate 
coated with 1µg of OVA or NP22-BSA and a standard ELISAMAX kit (Biolegend).  
 
Antibodies, Flow Cytometry, and Cell Sorting 
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Single-cell suspensions were obtained from spleen and treated with Fc-blocker for 10 
minutes on ice followed by staining with appropriate fluorochrome-labeled antibody or 
isotype controls for at least 20 minutes at 4°C. Cells were then washed with 10 volumes 
of PBS before resuspension in PBS for acquisition or Running Buffer (Miltenyi Biotech) 
for sorting. For intracellular staining, cells were fixed and permeabilized in appropriate 
buffers (Biolegend) followed by the addition of fluorochrome-labeled antibody. Cells 
were then washed two times with 10 volumes of permeabilization buffer and 
resuspension for acquisition. Flow cytometry samples were acquired using a FACSCanto 
cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star). Sorting was 
performed using FACSAria III (BD Biosciences) or MoFlo XDP (Beckman Coulter). 
Cell purity was confirmed at greater than 90% via flow cytometry. The following anti-
mouse antibodies were used: IgD, GL7, B220 (CD45R), CD21/35, CD23, CD38, CD80, 
CD138 (Biolegend). 
 
Quantitative real-time PCR 
Sorted GC B cells and plasma cells were suspended in TRIzol (Life Technologies) for 
lysis and storage, followed by RNA extraction described in the manufacturer protocol. 
RNA was used to transcribe cDNA using a Reverse Transcription Kit (Bio-Rad). 
Quantitative PCR was then performed on a Bio-rad MyiQ single-color RT-PCR detection 
system using SYBR Green Supermix (Bio-Rad). Primer sequences used: Blimp1 F‘5-
AGAGTGCACAGTGGAGAACG-3’; Blimp1 R‘5-GGTGCACAAATTGCGTAAAC-3’; 
Bcl-XL F‘5-TCCCGTAGAGATCCACAAAAGT-3’; Bcl-XL: R‘5-
GACAAGGAGATGCAGGTATTGG-3’. Gene expression was normalized to the β2-
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microblobulin (β-MG) housekeeping gene and represented data as the fold differences by 
the 2-ΔΔCt method, where the threshold cycle (ΔCt) = Ctarget gene - Ctβ-MG and ΔΔCt = 
ΔCtinduced – ΔCtreference. 
 
Imagestream Analysis 
Whole spleens were resuspended at 20 x 106 cells/mL in RPMI-1640 medium (Sigma, St. 
Louis, MO) (supplemented with 10% FBS, 5.5x10-5 M 2-ME, 100 units/ml-1 penicillin, 
and 100μg/mL-1 streptomycin (GIBCO, Waltham, MA)) and pre-warmed at 37°C for 30 
minutes. Cells were stimulated with 20μg/mL FITC-anti-IgM F(ab’)2 for indicated time 
points. Stimulation was immediately stopped by addition of PFA to 1.5%. Cells were 
washed with PBS and treated with Fc Blocker before antibody staining for surface 
molecules. Cells were then washed with PBS again followed by permeabilization with 
0.1% Triton-X 100 in Staining Buffer (PBS with 3% FBS, 0.02% Azide, and 2mM 
EDTA). Cells were then washed with Staining Buffer and incubated overnight at 4°C 
with antibodies for intracellular molecules. Cells were washed in Staining Buffer and 
incubated with secondary antibody if necessary, then resuspended in 100μL. Samples 
were acquired using the Amnis Imagestream-X (EMD Millipore) and analyzed with 
IDEAS software (EMD Millipore). Colocalization was calculated using the similarity 
feature. 
 
Statistical Analysis  
All quantitative data are shown as mean± s.e.m unless otherwise indicated. All samples 
were compared using two-tailed, unpaired Student’s T test. A P value less than 0.05 was 
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Global CD11b deficiency alters antibody production and GC formation in non-
autoimmune mice. 
To examine the effects of CD11b deficiency in an antigen-specific and non-
autoimmune Th2 setting, we crossed CD11-/- mice with the transgenic NP mouse model. 
These animals carry a pre-recombined BCR heavy chain variable locus that has affinity 
for the hapten NP (4-hydroxy-3-nitrophenylacetyl). The advantages of this system are 
twofold. Firstly, it allows NP antigen-specific cells to be identified via antibody staining. 
Secondly, these mice carry a higher frequency of innate anti-NP B cells, allowing for a 
greater scale response following immunization. NPtg CD11b-/- mice and NPtg CD11b+/+ 
controls were immunized with 50μg of NP-CGG (NP-chicken gamma globulin 
conjugate) suspended in Alum adjuvant. In mice, Alum causes a heavily polarized Th2-
type response that enhances antibody production (153). Alum has also been suggested as 
a preferential adjuvant for use over Complete Freund’s Adjuvant (CFA), which can cause 
harmful and interfering off-target effects (154). 
Animals were sacrificed at day 14 post-immunization to allow for full formation 
of the GC reaction and production of antibody-producing PCs. Anti-NP IgG effector-
class antibody was elevated in CD11b-knockout mice compared to controls. Baseline 
IgM class antibody was also increased in knockout mice, which is produced by non-class 
switched, non-GC B cells (Figure 1). These heightened antibody levels indicate a 
dysregulation of the B cell response to immunization in the absence of CD11b, revealing 
a role not limited to autoimmune reactions. 
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The notable increases in serum antibody then led us to investigate the status of 
GC and PC populations in this model. At 14 days after immunization, we did not observe 
any significant change in the total amount of GC B cells, averaging at 0.65% of splenic 
lymphocytes. However, when examining the NP-specific cell population, we did find an 
increased frequency of GCs, and both subsets were notably higher than their non-specific 
counterparts at roughly 1% and 2% for control and CD11b deficient animals, respectively 
(Figure 2). Examination of the PC population revealed higher frequency in knockout 
mice. Unlike the GCs, total PCs were increased in addition to the NP-specific subset 
(Figure 3). Increases in both of these populations suggest CD11b-negative regulation is 
able to limit the high affinity antibody response, though the antigen-restriction of this 
effect in GCs but not PCs implies a more dynamic effect between these stages of B cell 
maturation. 
To further profile these cells, we sorted GC B cells and PCs from immunized 
mice to assess expression of Bcl-XL, an anti-apoptotic and B-cell differentiation 
regulator, and Blimp1, which is vital for PC differentiation. For GCs, both Blimp1 and 
Bcl-XL were more highly expressed in knockout cells. PCs significantly increased 
Blimp1 expression, but not Bcl-XL (Figure 4). Together, these data demonstrate an 
antigen-restricted negative-regulatory role for CD11b on the maintenance of GC B and 
PC populations, which impacts the magnitude of the antibody response. 
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Figure 1: Increased antibody response in CD11b-knockout mice following 
immunization. NPtg CD11b-/- and NPtg CD11b+/+ mice were immunized with 50μg of 
NP-CGG suspended in Alum via i.p. injection. Serum was collected on day 14 post-
immunization. Anti-NP IgG and IgM antibody was measured via ELISA in plates coated 
with 1μg/well of NP-BSA. Optical density was measured at 450nm. Data are 
means±s.e.m. Summarized data are from at least three independent experiments. 





































































Figure 2: Germinal center B cells are increased in CD11b-knockout mice.  NPtg 
CD11b-/- and NPtg CD11b+/+ mice were immunized with 50μg of NP-CGG suspended in 
Alum via i.p. injection. Spleens were harvested on day 14 post-immunization. Gating 
strategy and representative dot-plots of control (top) and knockout (bottom) mice. 
Summarized data for GC frequency is shown on right. Data are means±s.e.m. 
Summarized data are from at least three independent experiments. *P<0.05 (unpaired 







Figure 3: Plasma cells are increased in CD11b-knockout mice.  NPtg CD11b-/- and 
NPtg CD11b+/+ mice were immunized with 50μg of NP-CGG suspended in Alum via i.p. 
injection. Spleens were harvested on day 14 post-immunization. Gating strategy and 
representative dot-plots of control (top) and knockout (bottom) mice. Summarized data 
for GC frequency is shown on right. Data are means±s.e.m. Summarized data are from at 











































Figure 4: CD11b deficiency alters GC and PC regulator expression. GCBs and PCs 
were sorted from immunized NPtg CD11b-/- and NPtg CD11b+/+ mice on day 14. RNA 
was extracted, used to transcribe cDNA, and RT-PCR was performed to examine gene 
expression of genes Bcl-XL and Blimp1. Data are means±s.e.m. Summarized data are 
from at least two independent experiments. *P<0.05; **P<0.001 (unpaired two-tailed 
Student’s t-test). 
  





















































CD11b Regulates Germinal Center B Cell BCR Signaling 
 Our previous study demonstrated the role of CD11b as a negative regulator of 
BCR signaling in vitro using the K46-17 B cell line transfected with a mutant form of 
human ITGAM. Here, we utilize the NP CD11b global knockout mouse model to 
examine BCR signaling on GC B cells ex vivo using Imagestream. This imaging flow 
cytometry provides microscopy visualization of cells based on flow cytometry gating, 
allowing for the acquisition of large numbers of events and rare cell populations that 
would be unobtainable using traditional confocal microscopy methods. These visual data 
can then be analyzed using associated software and provide quantitative numerical results 
to accompany qualitative visual images. Control and CD11b deficient mice were 
immunized in the same manner as previous experiments and splenocytes were analyzed 
at 14 days post treatment. Single cell suspensions of spleen were stimulated with FITC-
labeled anti-IgM Fab fragments lacking the Fc portion of the molecule, allowing for 
divalent binding of the BCR without nonspecific binding of Fc receptors found on B 
cells. 
 We first examined the impact of CD11b deficiency on BCR signaling molecules 
SHP-1, pLyn, and pSyk. As previously discussed, SHP-1 and pLyn negatively regulate 
the BCR signaling cascade by de-phosphorylating activation signals such as pSyk. 
Functional association of the BCR with each respective molecule was determined by 
measuring overlap of fluorescent signal across the cell, quantified as a colocalization 
score. BCR stimulation induced colocalization with negative regulator SHP-1 in both 
groups, but this was significantly reduced in CD11b knockout cells (Figure 5). In wild-
type cells, pLyn was colocalized with the BCR in the resting state, briefly separated after 
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5 minutes of stimulation, then rejoined by the 10-minute time point. CD11b deficient 
cells maintained a very low level of pLyn/BCR localization that was not altered by BCR 
ligation (Figure 6). When investigating pSyk, we did not see a significant change in 
colocalization with the BCR in CD11b deficient GC B cells versus controls (Figure 7). 
However, non-GC B cells did display a significant decrease in the absence of CD11b, 
suggesting differential regulation of this activator between B cell subsets (Figure 8). The 
decreased association of negative regulatory elements SHP-1 and pLyn with the BCR in 
knockouts show that CD11b serves as a signal regulator in the GC, consistent in its role 
shown with our previous data at the naïve B cell stage. 
Next we investigated the nuclear localization activity of cMyc and FOXO1, which 
are involved in GC survival and selection (144). A significant reduction in nuclear 
localization of cMyc was observed in CD11b deficient GC B cells both before and after 
stimulation (Figure 9). BCR stimulation caused an increase in cMyc nuclear activity in 
wild-type cells, but knockout-cell cMyc activity was less affected. FOXO1 nuclear 
translocation was also unchanged by anti-IgM stimulation in both groups, though there 
was a consistent significant reduction in knockout mice (Figure 10). The fate of GC B 
cells is driven by expression of these key regulators, which are activated by BCR and co-
receptor signaling. Altered nuclear utilization of FOXO1 and cMyc in the absence of 
CD11b reveals the downstream functional impact of its role in BCR negative regulation. 
The significant changes in these general B cell and GC B-specific factors outline a 




         
 
Figure 5: Loss of CD11b alters SHP-1 colocalization with the BCR. Single-cell 
suspensions of day 14 post-immunization spleens from NPtg CD11b-/- and NPtg 
CD11b+/+ mice were stimulated with 20μg/mL anti-IgM for given times. GC B cell 
colocalization of SHP-1 and BCR was measured via Imagestream, gated on B220+GL7hi 
events and defined by a similarity score greater than 1.25. Summary data for percentage 
of nuclear localized cells, representative similarity histogram, and representative images 
are shown. Data are means±s.e.m. *P<0.05 (unpaired two-tailed Student’s t-test). 
SHP-1 Co-localization





















        
 
Figure 6: Loss of CD11b alters pLyn colocalization with the BCR. Single-cell 
suspensions of day 14 post-immunization spleens from NPtg CD11b-/- and NPtg 
CD11b+/+ mice were stimulated with 20μg/mL anti-IgM for given times. GC B cell 
colocalization of pLyn and BCR was measured via Imagestream, gated on B220+GL7hi 
events and defined by a similarity score greater than 1.25. Summary data for percentage 
of nuclear localized cells, representative similarity histogram, and representative images 
are shown. Data are means±s.e.m. *P<0.05 (unpaired two-tailed Student’s t-test). 
pLyn Co-localization

























Figure 7: Loss of CD11b and pSyk colocalization with the BCR. Single-cell 
suspensions of day 14 post-immunization spleens from NPtg CD11b-/- and NPtg 
CD11b+/+ mice were stimulated with 20μg/mL anti-IgM for given times. GC B cell 
colocalization of pSyk and BCR was measured via Imagestream, gated on B220+GL7hi 
events and defined by a similarity score greater than 1.25. Summary data for percentage 
of nuclear localized cells, representative similarity histogram, and representative images 
are shown. Data are means±s.e.m. *P<0.05 (unpaired two-tailed Student’s t-test). 
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Figure 8: CD11b deficiency alters pSyk colocalization in non-GC B cells . Single-cell 
suspensions of day 14 post-immunization spleens from NPtg CD11b-/- and NPtg 
CD11b+/+ mice were stimulated with 20μg/mL anti-IgM for given times. Non-GC B cell 
colocalization of pSyk and BCR was measured via Imagestream, gated on B220+GL7- 
events and defined by a similarity score greater than 1.25. Summary data for percentage 
of nuclear localized cells, representative similarity histogram, and representative images 





Figure 9: Loss of CD11b alters cMyc Nuclear Translocation. Single-cell suspensions 
of day 14 post-immunization spleens from NPtg CD11b-/- and NPtg CD11b+/+ mice were 
stimulated with 20μg/mL anti-IgM for given times. GC B cell nuclear localization of 
cMyc was measured via Imagestream, gated on B220+GL7hi events and defined by a 
similarity score greater than 1. Summary data for percentage of nuclear localized cells, 
representative similarity histogram, and representative images are shown. Data are 
means±s.e.m. **P<0.001 (unpaired two-tailed Student’s t-test). 
cMyc Nuclear Localization



























Figure 10: Loss of CD11b alters FOXO1 Nuclear Translocation. Single-cell 
suspensions of day 14 post-immunization spleens from NPtg CD11b-/- and NPtg 
CD11b+/+ mice were stimulated with 20μg/mL anti-IgM for given times. GC B cell 
nuclear localization of FOXO1 was measured via Imagestream, gated on B220+GL7hi 
events and defined by a similarity score greater than 1. Summary data for percentage of 
nuclear localized cells, representative similarity histogram, and representative images are 
shown. Data are means±s.e.m. *P<0.05 (unpaired two-tailed Student’s t-test). 
FOXO1 Nuclear Localization

























B cell intrinsic CD11b regulates the Th2 antibody response 
The expression of CD11b on B cells and its impact on BCR signaling has been 
clearly demonstrated by our previous experiments. However, these studies have either 
taken place in vitro conditions or with in vivo global knockout models. The increased B 
cell response seen in our NP experiments could be caused by CD11b deficiency in 
several different cell types vital to the Th2 response and GC formation including Tfh 
cells, macrophages, and FDCs. To better elucidate the cell-specific importance of CD11b 
in this phenotype, we generated an inducible knockout model using the cre-lox system 
(Figure 11). We first crossed this strain with CD19-cre mice to study the effect of a B 
cell-restricted CD11b deletion. 
CD11bloxp/loxp and CD11bloxp/loxp; CD19-Cre littermates were immunized with 
OVA to induce a Th2 type reaction, analogous to our previous experiments. At 14 days 
post-immunization there was a significant increase in anti-OVA IgG antibody while an 
increase in antigen-specific IgM antibody was also observed, mimicking the phenotype of 
global CD11b knockouts (Figure 12). Examination of the GC frequency reveals a 
possible trending but not statistically significant increase in knockout mice. Surprisingly, 
the PC population was completely unaltered despite the observed increase in antibody 
response (Figure 13). Because of the high CD11b expression levels found on follicular, 
marginal zone, and memory B cells in our reporter studies, we investigated these 
populations as well; however, no difference in the frequencies of any of these B cell types 
was noted (Figure 14). These results suggest that B cell CD11b expression is regulating 






Figure 11: Generation of CD11b-loxp mice. CD11b conditional knockout mice were 
generated for this purpose of this study using CRISPR/Cas9. Construct design (top). 
Briefly, loxP elements were inserted into intron 2 and intron 5, resulting in loxP flank of 
exons 3 – 5 and causing a frame shift resulting in a truncated non-sense mediated decay 
protein. Example genotyping results are shown (bottom). The wild-type allele results in a 
283bp band, while the loxp mutant can be seen at 361bp.  
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Figure 12: B Cell loss of CD11b leads to increased serum antibody. CD11bloxp/loxp and 
CD11bloxp/loxp; CD19-Cre littermates were immunized 100μg of OVA suspended in Alum 
via i.p. injection. Serum was collected on day 14 post-immunization. Anti-OVA IgG and 
IgM antibody was measured via ELISA at given dilutions in plates coated with 1μg/well 
of OVA. Optical density was measured at 450nm. Data are means±s.e.m. Summarized 
data are from at least three independent experiments. *P<0.05; **P<0.01 (unpaired two-



































































Figure 13: The effect of B cell CD11b deletion on GC and PC formation. 
CD11bloxp/loxp and CD11bloxp/loxp; CD19-Cre littermates were immunized with 100μg of 
OVA suspended in Alum via i.p. injection. Spleens were harvested on day 14 post-
immunization. Summarized data and representative dot-plots for GCs (top) and PCs 






Figure 14: The effect of CD11b deletion on follicular, marginal zone, and memory B 
cells. CD11bloxp/loxp and CD11bloxp/loxp; CD19-Cre littermates were immunized with 
100μg of OVA suspended in Alum via i.p. injection. Spleens were harvested on day 14 
post-immunization. Summarized data and representative dot-plots for follicular and 
marginal zone (top) and PCs (bottom) are shown. Data are means±s.e.m. Summarized 




Myeloid cell loss of CD11b does not impact the Th2 antibody response 
With the conditional knockout model established, we used the lysosome 2 (Lyz2) 
cre system to specifically deplete CD11b expression in monocytes, macrophages, and 
neutrophils. While the Lyz2 cre model is widely used to study these cell types, its 
efficiency of deletion is not 100% and can vary greatly between tissue location and 
immune setting (155). Thus, we stained for CD11b in CD11bloxp/loxp; Lyz2-cre mice to 
determine the knockout efficiency and found a roughly 50% reduction of CD11b 
expression on myeloid cells (Figure 15). With this knowledge, we proceeded to examine 
the effect of this deletion in a Th2 immunization setting. Unlike our previous models, we 
did not observe any change in the IgM or IgG antibody response (Figure 16). The 
frequencies of GC and PC cells in the spleen were also unaffected (Figure 17). These 
results suggest that B cell expression of CD11b controls the heightened immune response 







Figure 15: Efficiency of Lyz2-cre driven deletion of CD11b B. Spleens from 
CD11bloxp/loxp and CD11bloxp/loxp; Lyz2-Cre littermates were stained with anti-CD11b 







Figure 16: Myeloid cell loss of CD11b does not alter the antibody response. 
CD11bloxp/loxp and CD11bloxp/loxp; Lyz2-cre littermates were immunized 100μg of OVA 
suspended in Alum via i.p. injection. Serum was collected on day 14 post-immunization. 
Anti-OVA IgG and IgM antibody was measured via ELISA at given dilutions in plates 
coated with 1μg/well of OVA. Optical density was measured at 450nm. Data are 




Figure 17: Myeloid cell loss of CD11b does not alter GC and PC differentiation. 
CD11bloxp/loxp and CD11bloxp/loxp; Lyz2-cre littermates were immunized with 100μg of 
OVA suspended in Alum via i.p. injection. Spleens were harvested on day 14 post-
immunization. Summarized data and representative dot-plots for GCs (top) and PCs 






Our previous in vitro work demonstrated how CD11b negatively regulates naïve 
B cell activation, while our in vivo studies utilized anti-snRNP transgenic mice and 
apoptotic cell immunization to demonstrate CD11b’s role in preventing autoimmunity. 
However, the function of CD11b as a regulator of the normal immune response was left 
unknown. As discussed earlier, unique mechanisms and pathways exist to regulate the 
immune response to different types of stimuli, including autoimmune signals. Whether 
CD11b functions as a general regulator of the B cell receptor or specialized in 
autoimmune responses remained to be determined. 
In the present work, we utilized a non-autoimmune setting to observe the effect of 
CD11b on B cells and GC formation in a general immune reaction. Using the NPtg model 
in a Th2-type immunization allowed us to increase the B cell response without inducing 
autoimmunity, as well as enabling identification the antigen-specific B cell response 
(156). We observed an increase in anti-NP IgM and IgG antibody in CD11b deficient 
mice, suggesting that this effect was not dependent on the autoimmune nature of the 
previous experiments. While CD11b can function as a negative regulator of downstream 
antibody-driven autoimmunity, it is not limited to typical autoimmune antigen activation. 
The increase in both switched IgG and non-switched IgM antibody also shows this 
regulation impacts antibody resulting from GC B cells as well as extrafollicular B cells. 
The “choice” between these two maturation pathways is governed by antigen recognition 
strength, thus implying that B cell CD11b regulation is not dependent on the intensity of 
BCR-antigen binding (157). Interestingly, we found an increase in the NP-specific GC B 
cell population of knockout mice, but not in the total or non-NP specific GCs. Contrary to 
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this, both NP-specific and non-NP-specific PCs were increased in absence of CD11b. 
This may be a result of the temporal nature of the GC and PC populations, which persist 
for roughly 3 weeks and 4 to 6 months, respectively (158). The GC B cells generated by 
recent NP immunization are limited to this antigen, while end-stage PCs generated by 
previous antigen responses still persist at a higher level than CD11b sufficient mice. This 
could be examined in future experiments by sequential immunization with different, 
traceable antigens and examination of the respective GC and PC populations. 
 Binding of the BCR promotes expression of survival signals to ensure longevity 
of the newly activated B cell during subsequent migration and differentiation. BCR 
ligation induces expression of NFκB, which regulates several transcription factors vital to 
B cell development and function. Among them is Bcl-XL, a member of the Bcl-2 family 
of survival factors. Bcl-XL overexpression in the GC has been linked to reduced 
apoptosis and increased survival of weak affinity GC B cells, which leads to excess 
differentiation to the memory B cell fate (159). Indeed, GCs from our CD11b deficient 
animals more highly expressed Bcl-XL, likely the result of increased BCR signaling. 
However, previous studies have demonstrated that Bcl-XL overexpression alone does not 
increase the GC frequency or serum antibody response in an NP immunization model 
(160). This suggests that additional essential signals are more highly expressed in the 
absence of CD11b. Bcl-XL expression has also been shown to be vital during plasma cell 
differentiation in preventing ER stress-induced death (161). Increased expression of Bcl-
XL in the PCs of CD11b deficient mice is likely driving increased survival of this 
population during differentiation. This compounded with the increase in their GC 
progenitors results in significant increase in total PCs. Blimp-1 was upregulated in 
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knockout PCs as well. Expression of Blimp-1 increases as GC B cells downregulate Bcl-
6 and exit the germinal center to differentiate into PCs, where it continues to increase in 
expression and drive PC maturity (162). Blimp-1 is also required for PC antibody 
secretion, suggesting that the IgG increase seen systemically may also be increased at the 
individual cell production level (163). Though NFκB can directly bind the Blimp-1 
promoter (prdm1), it is not sufficient to induce its transcription alone (164). Additional 
signals from CD40 and IL-21 engagement are required to fully induce Blimp-1 and PC 
differentiation (165). Thus, the increase in PC Blimp-1 expression is likely not a direct 
effect of increased BCR signaling in the absence of CD11b, but rather a downstream 
consequence of increased GC B cell-Tfh interaction at the GC stage driven by enhanced 
BCR signaling. 
 The BCR signaling cascade acts through and is regulated by phosphorylation-
controlled proteins such as Syk and SHP-1. In this study, we were able to expand upon 
our previous findings using in vitro B cell line models to demonstrate the effects of 
CD11b deletion on primary cells ex vivo at the GC B stage. In the absence of stimulation, 
BCRs cluster into autoinhibitory confirmations. Indeed, our previous work demonstrated 
CD11b has a stabilizing effect on CD22, which maintains the inhibitory cluster state to 
control tonic BCR signaling (166). Binding of antigen causes dispersal of these clusters, 
opening up immunoreceptor tyrosine-based activation motifs (ITAMs) on the 
cytoplasmic portions of associated CD79 which in turn recruit downstream signals such 
as Lyn and Syk (167, 168). In GC B cells, we did not observe a significant change in 
pSyk colocalization with BCR following ligation in the absence of CD11b. However, 
non-GC B cells did demonstrate a defect in pSyk-BCR colocalization in the naïve 
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condition, implying pSyk is less important in GC-B cell signaling than non-GCs. 
Additionally, a small amount of BCR capping can be seen at the resting state in non-GC 
knockout cells. Perhaps CD11b is acting as a regulator of tonic signaling at the non-GC 
stage, producing some BCR cap formation in its absence, but is less important at the GC 
stage. BCR-pLyn colocalization was decreased in CD11b deficient cells, demonstrating 
its involvement in maintaining the pLyn negative regulatory circuit at the GC B cell 
stage. Similarly, SHP-1 recruitment to the BCR region was decreased in the absence of 
CD11b. These observations confirm CD11b’s function in the regulatory circuit of BCR 
activation at the GC stage, suggesting an impactful role on light-zone affinity-driven 
selection. Whether it is serving a specific regulatory purpose at this stage or simply 
retaining its function as a permanent feature of the BCR circuit has yet to be determined. 
CD11b may be contributing to the high activation levels of SHP-1 that drive dampened 
BCR signaling within the GC (142). This novel finding of CD11b BCR regulation at the 
GC stage builds upon our previous work with a naïve B cell line and suggests the 
possibility of regulatory roles for CD11b at other stages of B cell maturation and 
development. 
 The GC reaction is tightly controlled by several transcriptional regulators. Among 
them are FOXO1 and cMyc. FOXO1 instructs the dark zone side of the reaction and 
shares many cooperative functions with master GC regulator Bcl6 (145). We observed a 
decrease in the nuclear localization of FOXO1 following BCR ligation in CD11b 
deficient cells. In the GC, BCR engagement is restricted to the light zone as newly 
mutated GC B cells exit the dark zone and compete for uptake of cognate antigen from 
FDCs. As FOXO1 is limited to the dark zone, its function may be downregulated by 
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increased BCR signaling that is further exacerbated by absence of CD11b negative 
regulation. Conversely, cMyc is not expressed in proliferating dark zone GC B cells, and 
is vital in GC maintenance, formation, and positive selection in the light zone (146). 
Surprisingly, CD11b deficient cells had significantly less nuclear localization of cMyc at 
the steady state and after BCR ligation. This may be a result of downstream negative 
regulatory elements compensating for the increased signaling resulting from CD11b’s 
absence. Alternatively, CD11b may have an unknown function related to the nuclear 
utilization kinetics of cMyc. Other studies have utilized additional signals present in Tfh-
GC B cell interactions to examine cMyc, such as CD40L. The absence of these signals 
may be influencing the effects seen here and should be incorporated in future 
experiments. Despite this, these data outline a role for CD11b negative regulation of BCR 
signaling at the GC stage of B cell development. Loss of function ITGAM mutations in 
SLE patients may be contributing to disease by increased BCR activation during this 
critical process, resulting in increased production of high-affinity antibody-producing 
PCs. 
 The generation of CD11b-flox mice allowed us to examine the specific 
contributions of different cell types to this phenotype. Use of a CD19-Cre model to 
eliminate B cell CD11b expression was able to replicate the increase in serum IgG and 
IgM seen in the global knockout, but not the increases in GC and PC frequencies. 
However, in global CD11b knockout mice, only the NP-specific fraction of GCs was 
increased while the total was unchanged. The inability to replicate this phenotype in the 
B cell-specific knockout could be due to the lack of an increased antigen-specific naïve B 
cell population present in the NP mouse model. Combining the NP model with the tissue-
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specific CD11b knockout could reveal the potential effects of this antigen bias. The lack 
of increase in the PC population was unexpected, as both NP-specific and total PC 
fractions were higher in global knockouts. This suggests that B cell CD11b deficiency is 
not sufficient to increase PC differentiation. However, increases in serum antibody 
indicate that these PCs are hyperactive, producing greater amounts of IgG and IgM at the 
individual cell level. This can be confirmed with future in-vitro stimulation experiments. 
Despite the relatively high populations of CD11b expressing memory B cells 
found in our reporter model, we did not observe any changes in these subsets in B cell 
CD11b knockout mice. In memory B cells, CD11b has been shown to be vital to 
trafficking and migration, especially in the peripheral blood (169). As these cells were of 
the spleen, loss of CD11b may be less impactful. Additionally, memory B cell generation 
is still ongoing at 14 days post-immunization. Investigation at the 4-week timepoint 
would provide a more complete model of the memory B response (170, 171). 
Decision between the marginal zone and follicular B cell fate is governed by the 
strength of BCR signaling (172). A previous study demonstrated deletion of BCR 
negative regulator CD22 resulted in a reduction in marginal zone B cells in favor of the 
follicular compartment (173). Despite this, we did not observe any changes in these 
populations in B cell CD11b knockout mice. This suggests that CD11b does not play a 
significant role in BCR signal regulation at this stage. 
CD11b expressing myeloid cells are known to be important in the priming and 
expansion of B cells during an alum immunization reaction (174, 175). Even CD11b 
expressing myeloid-derived suppressor cells (MDSCs) have been shown to enhance B 
cell antibody production in certain settings (176, 177). Interestingly, CD11b expressing 
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myeloid cells were found to suppress lupus-like disease in male, but not female, NZB 
mice (178). Depletion of CD11b expressing neutrophils can even cause accelerated 
disease in both genders of these mice (179). However, usage of myeloid cell expressed 
lysosome-cre driven conditional knockout was unable to replicate any of the enhanced B 
cell response phenotypes seen in our global knockout animals. In these cells, most 
notably macrophages and neutrophils, CD11b functions in cell-cell adhesion and 
trafficking to sites of inflammation. Our results imply that defects in this mechanism are 
not sufficient to alter the ability of these cells to enhance the B cell response, and perhaps 
they maintain adequate trafficking through other pathways. Marginal zone macrophages 
are essential for B cell follicle trafficking and GC formation, but this subset expresses 
minimal levels of CD11b and is likely unaffected by deletion or mutation (180, 181).  
Alternatively, the non-significant changes in these mice may be due to the inefficiency of 
the lysosome-cre knockout model, which was only able to reduce expression by an 
average of 50%. 
 These experiments have demonstrated that CD11b is able to regulate the humoral 
response in a B cell intrinsic manner. We have revealed novel BCR signaling regulation 
by CD11b at the GC B cell stage and its downstream effect on antibody production 
(Figure 18). This data suggests a widespread function for CD11b regulations of the BCR 
across different B cell subsets and warrants the investigation of its potentially novel role 




Figure 18: Loss of CD11b alters GC B cell signaling and regulation and enhances 
















The identification of CD11b as a regulator of B cell BCR signaling at the GC and 
naïve B cell stages has revealed the possibility of roles in other B cell subsets as well. 
Preventing unwanted stimulation of B cells via BCR negative regulation is vital at every 
step of B cell development. However, mechanisms of regulation are dynamic. As 
discussed in the previous chapter, various surface BCR co-receptors specialize in 
negative regulation in response to specific ligands, such as CD72 and Sn/RNP. The 
varying necessities of B cells at different stages of maturity may require more or less 
regulation from a given receptor mechanism. Whether regulation by CD11b has similar 
restrictions remains to be determined. To effectively study CD11b regulation of the BCR, 
its expression on different B cell subsets must be examined. 
BCR Signaling In B Cell Differentiation 
As the hallmark receptor of B cells, the BCR acts as an important signaling 
pathway at all stages of development and differentiation. Understanding of the BCR’s 
function at various B cell stages is necessary to better examine the potential role of 
CD11b as a negative regulator. Expression of the BCR begins in the early development 
within the bone marrow, as immature B cells express the pre-BCR which features a 
V(D)J recombined heavy chain and a temporary surrogate light chain (182). Even this 
pre-BCR stage engages in ligation and activation pathways to drive selection of 
functional heavy-chains (183). After the addition of a recombined light chain, BCR 
signaling is once again vital to filter out autoreactive B cells from the newly formed 
repertoire (184). By the mature B cell stage, expression of the IgM-BCR is subject to 
activation and negative regulation via previously discussed pathways. The IgD-BCR can 
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also be expressed in these cells. The molecular pathways involved in IgD activation and 
negative regulation have been shown to differ from that of IgM, but overall remain 
poorly understood (139). BCR signaling strength governs the differentiation between 
marginal zone and follicular B cells fates, with higher levels of signal favoring the latter 
(185). At the follicular stage, antigen encounter via the BCR enhances activation and 
drives migration to the T zone to receive T cell signal (186, 187). After T-B interaction, 
B cell fate is governed by affinity. BCRs with high affinity have stronger BCR signaling 
and receive more T cell help, driving them to extrafollicular plasma cell differentiation 
(157). As discussed in the previous chapter, BCR signaling in the GC is minimal due to 
high activation of negative regulator SHP-1. B cells with lower yet still competitive 
affinity enter the GC. Regulation of the BCR signal is crucial during all of these 
processes to ensure a proper B cell response that prevents the unwanted activation of off-
target cells yet promotes the correct fate for needed effectors. Our identification of 
CD11b as a novel BCR regulator reveals the need to re-examine its presence in different 
B cell subsets. 
Known Roles of CD11b in B Cells 
Despite its classic association with myeloid cells, CD11b expression has been 
identified on B cells for many years (188). However, the function and purpose of B cell 
CD11b is still not well established. One initial study to examine these cells found that 
CD11b is expressed more on CD27+IgD- memory B cells than other peripheral B cell 
populations. These cells were demonstrated to migrate in vitro more effectively than 
CD11b- subsets, suggesting a role in homing ability for memory B cells (169). 
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A small subset of B1 B cells, roughly 10%, expresses CD11b. These cells were 
found to specialize in stimulation and expansion of CD4+ T cells and produced far less 
IgM than the majority CD11b- subset. In SLE patients, the CD11b+ population is 
increased three-fold and have enhanced T cell stimulation activity (189). These same 
cells have also been shown to produce IL-10 and suppress T cells activation, 
demonstrating a two-fold role in regulation of T cells (190). In mice, B1 CD11b 
expression has been suggested as an indicator of the development stage (191). IL-10 
dependent CD11b+ B cells have also been described as T cell regulators in autoimmune 
hepatitis mice (192). 
A CD11b expressing population of plasma cells has also been described. These 
intestinally-located plasma cells reside in the Peyer’s patch, and produce higher amounts 
of IgA antibody than CD11b- cells. They also proliferate more rapidly and are dependent 
on IL-10. These CD11b+ plasma cells are important for early IgA responses in the 
intestine following oral immunization (193).  
CD11b (also known as complement receptor 3 (CR3)) expression in IgM+ splenic 
B cells was found in relation to complement component 3 (C3). In C3 deficient animals, 
previously unseen expression of CD11b was found to be 2 to three-fold higher than C3 
sufficient mice (194). This was determined to be an effect driven by lack of 
environmental C3, as B cells from wild-type animals began to express more CD11b after 
transfer into C3-/- mice. These findings describe a role for C3 in controlling the 
expression of CD11b on B cells, though the purpose of this function is still unclear. 
Despite these known CD11b expressing B cell populations, the role of CD11b in 
B cells remained largely unstudied. Demonstration of CD11b as a novel BCR regulator 
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requires the re-examination of CD11b in these previously described subsets. The 
presence of CD11b across B cell subsets must also be re-evaluated given the implication 
of these new findings on immune regulation. 
In this study, we examine CD11b expression on various B cell subsets using an 
endogenous CD11b-GFP reporter. We identify previously unreported populations of 
CD11b expressing cells. Interestingly, these expression patterns change during the 
immune state, revealing a dynamic role for CD11b in BCR regulation. CD11b expression 
in Faslpr autoimmunity is also examined. In these animals, B cell CD11b patterns are 
altered with disease progression, and fundamentally changed from the naïve and healthy 
immune settings.   
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MATERIALS AND METHODS 
 
Mice 
CD11b reporter (FRT) mice were generated for the purpose of this study. Lupus-prone 
CD11b reporter Faslpr/lpr-FRT mice were generated by interbreeding FRT mice with 
Faslpr/lpr mice (The Jackson Laboratory). Lupus-prone CD11b reporter ABIN1-FRT mice 
were generated by interbreeding FRT mice with ABIN1[D485N] inactive ABIN1 knock-
in mice (a gift from Dr. David Powell). Mice at 6–8 weeks of age with both sexes were 
used for immunization experiments. Aged mouse experiments were used at the indicated 
timepoints. All mice were housed and bred in a conventional facility at the University of 
Louisville. Animal care and experiments were conducted in accordance with the National 
Institutes of Health guidelines and were approved by the Institutional Animal Care and 
Use Committee at the University of Louisville. 
 
Immunizations and Ab Detection 
FRT-reporter mice were immunized via intraperitoneal (i.p.) injection of 100μg OVA 
peptide in Alum adjuvant at a 1:1 ratio. Sera was collected before and at given time-
points after immunization, or at noted time-points in aged mice. Anti-OVA and antibody 
titers were measured via enzyme-linked immunosorbent assay (ELISA) using a 96-well 
plate coated with 1µg of OVA and a standard ELISAMAX kit (Biolegend). Mouse anti-
dsDNA antibody was detected using an anti-dsDNA ELISA kit (Signosis Inc).  
 
Antibodies, Flow Cytometry, and Cell Sorting 
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Single-cell suspensions were obtained from spleen or bone marrow and treated with Fc-
blocker for 10 minutes on ice followed by staining with appropriate fluorochrome-labeled 
antibody or isotype controls for at least 20 minutes at 4°C. Cells were then washed with 
10 volumes of PBS before resuspension in PBS for acquisition or Running Buffer 
(Miltenyi Biotech) for sorting. For intracellular staining, cells were fixed and 
permeabilized in appropriate buffers (Biolegend) followed by the addition of 
fluorochrome-labeled antibody. Cells were then washed two times with 10 volumes of 
permeabilization buffer and resuspension for acquisition. Flow cytometry samples were 
acquired using a FACSCanto cytometer (BD Biosciences) and analyzed using FlowJo 
software (Tree Star). Sorting was performed using FACSAria III (BD Biosciences) or 
MoFlo XDP (Beckman Coulter). Cell purity was confirmed at greater than 90% via flow 
cytometry. The following anti-mouse antibodies were used: Gr-1, NK1.1, IgD, IgM, 
GL7, B220 (CD45R), CD3, CD11b, CD11c, CD21/35, CD23, CD38, CD43, CD80, 
CD138 (Biolegend). 
 
BCR Repertoire Sequencing 
Sort-purified cells were frozen in TRIzol (Life Technologies) for lysis and storage. RNA 
isolation was performed using chloroform extraction and an RNEasy Micro Kit (Qiagen). 
 
Statistical Analysis  
All quantitative data are shown as mean± s.e.m unless otherwise indicated. All samples 
were compared using two-tailed, unpaired Student’s T test. A P value less than 0.05 was 








B Cell CD11b expression is altered in a Th2 immunization setting. 
Our previous data has clearly defined an effect of CD11b expression on the naïve 
B, GC B, and plasma cell stages. However, expression of CD11b at each stage of B cell 
development is not well characterized. In order to examine this, we generated a CD11b-
reporter mouse model, described as “FRT”, which adds a GFP tag to the CD11b promoter 
site (Figure 19). Though CD11b expression on B cells has been demonstrated to be very 
low, this system allows for a more sensitive quantification directly controlled by 
transcription and expression of CD11b rather than traditional antibody staining which can 
be subject to nonspecific binding effects. 
 We first sought to investigate any changes in CD11b expression in an 
immunization setting compared to a naïve state. A Th2-type immunization was used to 
build upon our previous studies using global CD11b knockout mice. Beginning at the 
early stages of development, we examined the pre-pro B, pro B, pre B, and immature B 
cell populations in the bone marrow. Expression was greatest at the earliest pre-pro B cell 
stage, and increased even further after immunization (Figure 20). In the intermediate pro 
B and pre B stages, the CD11b expressing fraction was minimal, averaging less than even 
1% of the total population (Figure 21). By the immature B cell phase, expression elevated 
slightly, and  was once again increased in the immune setting. As a whole, the 
developmental stages of B cells have minimal levels of CD11b expression compared to 
other subsets. Thus, it is unlikely that CD11b is playing a significant role in regulation of 
their pre-BCR and BCR signaling. 
 In the peripheral lymphoid organs, we revealed CD11b expression in the follicular 
and marginal zone B cells of the spleen. The follicular B compartment revealed a low but 
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very well-defined population of CD11b expressing cells (Figure 22). Interestingly, 
expression decreased by nearly half after immunization. The marginal zone CD11b+ 
subset was larger, and also showed a similar decrease in immunized mice. Though the 
marginal zone CD11b expressing frequency is higher than that of the follicular B cell 
subset, it is less well defined against the CD11b-negative population. Also within the 
spleen, we examined GC B cells to reveal an average of 2% of naïve GC B cells express 
CD11b which decreased by nearly half following immunization (Figure 23). Due to the 
relatively low frequency of GC B cells, the CD11b expressing subset is very rare and 
poorly-defined compared to larger populations of B cells. Post-GC long-lived memory B 
cells reside in the spleen as well. Naïve levels of CD11b in these cells increased 
dramatically after Th2 immunization, though with some variation (Figure 24). The 
presence of CD11b on memory B cells is unsurprising given previous reports, but the 
discovery of CD11b expressing populations within the follicular, marginal zone, and GC 
compartments is novel. Though the frequency is low, these subsets are easily 
distinguished from the CD11b- population and may be playing a key role in regulation of 
the BCR in these cells.  
 Among the B cell subsets examined, the plasma cells carry the most consistently 
high amounts of CD11b expression. An average of 12% of splenic-resident short-lived 
plasma cells express CD11b in the naïve state, which decreased after immunization 
(Figure 25). Surprisingly, the opposite effect was observed in bone marrow-resident long-
lived plasma cells. Here, naïve CD11b expression averaged at roughly 8% and increased 
after immunization (Figure 26). These findings build upon the previous identification of 
CD11b expressing plasma cells in the Peyer’s patch. However, the opposing shift in 
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expression under immunization conditions indicates a differential role for CD11b in these 
two closely related but distinct populations. The varying changes in expression across all 







Figure 19: Generation of CD11b-Reporter mice. CD11b reporter mice were generated 
for this purpose of this study using. Construct design (top). Briefly, GFP was inserted 
into the promoter region of the third exon of CD11b using a loxp-neo cassette. To verify 
reporter effectiveness, spleen cells from FRT mice were stained with CD11b-APC 





Figure 20: The impact of immunization on CD11b expression in early-stage 
developing B cells of the bone marrow. FRT mice were immunized with 100μg of 
OVA suspended in Alum via i.p. injection. Bone marrow was harvested on day 14 post-
immunization alongside naïve littermates. Gating strategy for identifying pre-pro and pro 
B cells (top) and representative dot-plots for CD11b expression (bottom) are shown. 
Reporter-negative littermates were used as referential controls, shown by ▲. 
Summarized data are from at least three independent experiments. **P<0.001 (unpaired 




Figure 21: The impact of immunization on CD11b expression in later-stage 
developing B cells of the bone marrow FRT mice were immunized with 100μg of OVA 
suspended in Alum via i.p. injection. Bone marrow was harvested on day 14 post-
immunization alongside naïve littermates. Gating strategy for identifying pre B and 
immature B cells (top) and representative dot-plots for CD11b expression (bottom) are 
shown. Reporter-negative littermates were used as referential controls, shown by ▲. 
Summarized data are from at least three independent experiments. *P<0.05 (unpaired 




Figure 22: The impact of immunization on CD11b expression in splenic marginal 
zone and follicular B cells. FRT mice were immunized with 100μg of OVA suspended 
in Alum via i.p. injection. Spleens were harvested on day 14 post-immunization 
alongside naïve littermates. Gating strategy for identifying marginal zone and follicular B 
cells (top) and representative dot-plots for CD11b expression (bottom) are shown. 
Reporter-negative littermates were used as referential controls, shown by ▲. 
Summarized data are from at least three independent experiments. *P<0.05, **P<0.0001 




Figure 23: The impact of immunization on CD11b expression in splenic GC B cells. 
FRT mice were immunized with 100μg of OVA suspended in Alum via i.p. injection. 
Spleens were harvested on day 14 post-immunization alongside naïve littermates. Gating 
strategy for identifying GC B cells (top) and representative dot-plots for CD11b 
expression (bottom) are shown. Reporter-negative littermates were used as referential 
controls, shown by ▲. Summarized data are from at least three independent experiments. 





Figure 24: The impact of immunization on CD11b expression in splenic memory B 
cells. FRT mice were immunized with 100μg of OVA suspended in Alum via i.p. 
injection. Spleens were harvested on day 14 post-immunization alongside naïve 
littermates. Gating strategy for identifying memory B cells (top) and representative dot-
plots for CD11b expression (bottom) are shown. Reporter-negative littermates were used 
as referential controls, shown by ▲. Summarized data are from at least three independent 





Figure 25: The impact of immunization on CD11b expression in splenic plasma 
cells. FRT mice were immunized with 100μg of OVA suspended in Alum via i.p. 
injection. Spleens were harvested on day 14 post-immunization alongside naïve 
littermates. Gating strategy for identifying plasma cells (top) and representative dot-plots 
for CD11b expression (bottom) are shown. Reporter-negative littermates were used as 
referential controls, shown by ▲. Summarized data are from at least three independent 





Figure 26: The impact of immunization on CD11b expression in long lived bone 
marrow plasma cells. FRT mice were immunized with 100μg of OVA suspended in 
Alum via i.p. injection. Spleens were harvested on day 14 post-immunization alongside 
naïve littermates. Gating strategy for identifying plasma cells (top) and representative 
dot-plots for CD11b expression (bottom) are shown. Reporter-negative littermates were 
used as referential controls, shown by ▲. Summarized data are from at least three 




Progression of lupus-like disease in mice impacts B cell expression of CD11b 
 Given the effectiveness of the FRT reporter system for examining B cell 
expression of CD11b in the immunization setting, we sought to utilize it in lupus-like 
models for increased disease-relevance. The Faslpr mouse strain carries a loss of function 
mutation for the Fas gene, which is vital to Fas-FasL interaction and driving apoptosis of 
lymphocytes. This defect causes immense lymphoproliferation and lymphadenopathy, 
glomerulonephritis, and systemic autoimmunity, and is widely used as a murine model 
for SLE in both the MRL and B6 backgrounds (195, 196). We crossed this line with our 
FRT reporter strain to obtain FRT-Faslpr mice. Expression of CD11b on relevant B cell 
populations was observed from early life through disease onset at 3 months, which was 
confirmed by high titers of anti-dsDNA autoantibody in the serum (Figure 27). 
 The follicular and marginal zone B cells of the spleen showed very low 
expression of CD11b. This level was not affected with the progression of lupus-like 
disease (Figure 28). The splenic memory B cell CD11b+ population was much lower than 
that observed in healthy animals, and appeared to decrease as disease progressed. Though 
expression was initially very low in the GCs, they too revealed a decreased expression 
with age. By 4 months old, CD11b expression was nearly indistinguishable from the 
autofluorescence of reporter-negative controls. 
 The CD11b expressing fraction of splenic PCs was much higher than all other 
subsets, similar to observations in the healthy immunization model. At the earliest time 
point, an average of 4.5% expression can be seen which then steadily falls to nearly 
undetectable levels by month 4 (Figure 29). Long-lived bone marrow PCs conversely 
maintain CD11b expression over time, though with some volatility.  
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 The early developmental stages of B cells all display extremely low amounts of 
CD11b in this model; all below 1% average expression (Figure 30). However, they do 
maintain a consistent pattern of expression with healthy animals; demonstrating notable 
CD11b expressing populations in the pre-pro and immature fractions while expression in 
the pro B and pre-B stages is minimal. Progression of disease appears to have no impact 
on these cells, with a slight increase in immature B cells being the exception. 
 As a whole, CD11b expression in B cells is much lower in the Faslpr disease state 
than in healthy animals. With the exception of plasma cells, all B cell subsets appear to 
have negligible CD11b expressing populations. Whether this is an effect of lupus-like 






Figure 27: Progression of autoimmune disease in FRT-LPR mice. Faslpr/lpr were 
crossed with the CD11b-reporter FRT strain to obtain FRT-Faslpr/lpr animals. Progression 
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Figure 28: Faslpr autoimmune disease impacts splenic B cell CD11b expression. FRT-
Faslpr animals were aged to 1 month, 2 months, 3 months, or 4 months before sacrifice. 
Splenic populations of follicular, marginal zone, memory, and GC B cells were identified 
as previously shown above. Reporter-negative littermates were used as referential 





Figure 29: Faslpr autoimmune disease impacts plasma cell CD11b expression. FRT-
Faslpr animals were aged to 1 month, 2 months, 3 months, or 4 months before sacrifice. 
Splenic and bone marrow populations of PCs were identified as previously shown above. 
Reporter-negative littermates were used as referential controls, shown in red. A minimum 






Figure 30: Faslpr autoimmune disease impacts developmental B cell CD11b 
expression. FRT-Faslpr animals were aged to 1 month, 2 months, 3 months, or 4 months 
before sacrifice. Bone marrow populations of developing B cells were identified as 
previously shown above. Reporter-negative littermates were used as referential controls, 




Comparison of the CD11b-expressing plasma cell repertoire. 
Advances in high-throughput sequencing have allowed for large-scale analysis 
and immune profiling of the BCR repertoire in a given population. This technique has 
been used to study a number of autoimmune disorders, as well as assist in antibody 
discovery (197, 198). The established role for CD11b in downregulation of autoimmune 
activation suggests that its expression on B cells may correlate with a unique antigen 
specificity profile. Thus, we sought to utilize this technique to compare the BCR 
repertoires of the CD11b expressing and non-expressing PC subsets. 
To examine this, we crossed our FRT reporter strain with the ABIN1 lupus-like 
model. A20-binding inhibitor of NF-κB (ABIN1) is a ubiquitin-binding protein that was 
identified as a SLE susceptibility loci in genome-wide association studies (199, 200). The 
ABIN1D485N strain carries a non-functional mutant form of human ABIN1 (D485N) and 
has been used in several studies of B cell autoimmunity and as a mouse model of lupus 
(201-203). Additionally, this system is not subject to the bias of the Faslpr model whose 
lack of Fas-FasL interaction heavily skews selection of the B cell population. Progression 
of autoimmune disease in FRT-ABIN1 mice was confirmed via serum levels of anti-
dsDNA IgG antibody (Figure 31). In a preliminary study, 5 month old ABIN1 animals 
displayed distinct CD11b expression in the PC population with subsets ranging from 3.7 
to 25.7% (Figure 32). isolated the paired CD11b expressing and non-expressing subsets 
from individual animals for BCR repertoire sequencing and comparison. This is an 
ongoing study, and we expect analysis of these BCR repertoires to provide meaningful 
insight into the properties of the CD11b expressing plasma cell population. We will also 
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determine if CD11b expression is protective against the autoimmunity or nephritis that 





Figure 31: Progression of autoimmune disease in FRT-ABIN1 mice. ABIN1D485N 
mice were crossed with the CD11b-reporter FRT strain to obtain FRT-ABIN1 animals. 
Progression of autoimmune disease was confirmed by measurement of anti-dsDNA IgG 
antibody at given time-points. 
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Figure 32: FRT-ABIN1 plasma cell CD11b expression. FRT-ABIN1 animals were 
aged to 5 months. The splenic population of PCs was identified as previously shown 





The identification of CD11b as a regulator of BCR signaling revealed the 
potential for CD11b expression in multiple B cell subsets. As CD11b is conventionally 
associated with myeloid cells, its presence on B cell populations has been largely 
overlooked. We have demonstrated novel sub-populations of CD11b expressing B cells 
in multiple subsets, which are dynamically influenced by immune setting. 
CD11b expressing B cell subsets have been previously identified, namely in the 
memory B cell, B1 B cell, and Peyer’s patch resident plasma cell subsets (169, 189, 193). 
Using a CD11b reporter, we were able to identify several more populations of CD11b+ B 
cells in immunization and autoimmune conditions. Early stages of B cell development in 
the bone marrow have extremely low CD11b expressing populations, suggesting CD11b 
does not impact B cell development in a significant way. Germinal center B cells of the 
spleen retained a relatively small population of CD11b expressing cells, which decreased 
even further after immunization. Our reporter model confirmed previous reports of a 
substantial CD11b expressing fraction of memory B cells. This expression increased 
following immunization, which is likely to assist in migration and tissue homing 
following generation as previously shown (169). Memory B cell CD11b expression was 
lower in autoimmune mice and decreased further with disease severity, which may be 
indicative of a regulatory role breakdown in addition to function in migration. Follicular 
and marginal zone B cells express CD11b at a comparatively lower level, which was 
significantly reduced after immunization. Indeed, in lupus-prone mice, CD11b expression 
was nearly absent in these cells, and did not change over the course of disease. 
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In MRL-lpr lupus mice, autoreactive B cells are able to avoid follicular exclusion 
due to lack of Fas-FasL selection and become major producers of anti-dsDNA antibody 
(204). It is possible that populations of CD11b expressing B cells in which CD11b is 
actively serving as a negative regulator are being outcompeted by these autoreactive B 
cells unchecked by Fas-FasL deletion. Thus, the fraction of CD11b+ B cells in these 
subsets is dwarfed by the CD11b-, resulting in a much lower frequency in the total 
population.   
Expanding upon the CD11b expressing plasma cells previously identified in the 
Peyer’s patch, we observed CD11b positive populations of both splenic and bone marrow 
resident PCs. In the splenic population, which are typically short-lived PCs, CD11b 
expression decreased following immunization. The aforementioned CD11b expressing 
Peyer’s patch PCs were found to proliferate and produce antibody at a higher rate than 
CD11b- cells. Increased CD11b expression may serve as a negative regulator to better 
control these hyper-responsive cells. Splenic PC CD11b could function in a similar role 
by tempering the response of newly formed PCs, which carry reduced expression as they 
complete differentiation and exit the GC (Figure 33). Conversely, long-lived PCs of the 
bone marrow increased CD11b expression following treatment. Long-lived PCs do not 
activate and respond to BCR binding antigen or immune complex, but rather exist to 
provide persistent antibody after initial encounter with antigen (114, 205). Here, high 
CD11b expression may serve as an additional layer of regulation to prevent BCR signal 
activation of these cells and maintain a steady state of antibody production. In Faslpr 
mice, both bone marrow and splenic PCs lost CD11b expression over time. Like the 
memory B cells, this is likely related to increased severity of disease as freshly formed 
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PCs of the spleen lose regulatory elements and the migratory pattern of long-lived PCs is 
altered by a chronic state of immune response. 
 
 
Figure 33: CD11b is dynamically expressed across different B cell subsets 
 
The variability in CD11b expression patterns seen across these B cell populations 
demonstrates its role as a dynamic regulator that serves the need of different functional 
niches. In splenic memory B cells and long-lived plasma cells of the bone marrow, 
increased expression of CD11b is following immunization may providing increased 
protection against unwanted activation. These B cell types are potent mediators of 
secondary responses, and increased CD11b downregulation of BCR signaling can prevent 
a pathogenic hyper-production of antibody. Conversely, the marginal zone, follicular, 
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germinal center, and short-lived splenic plasma cells all reduced CD11b expression in the 
Th2 response. These are the formative and transient mediators of humoral immunity, 
acting to generate a response and persist only long enough to permit clearance of 
pathogen before dying off. Decreased expression of negative regulator CD11b during the 
crucial stages of the humoral immune reaction can allow for more effective engagement 
of the BCR, enhancing B cell differentiation and subsequent antibody response. 
Comparatively increased CD11b expression during the naïve state could be acting as a 
prevention mechanism of acute autoimmune activation, restricting BCR engagement until 
a true systemic immune reaction takes place. 
Examination of CD11b in the disease state will require more thorough studies. 
The B cell selection bias of the Faslpr model alters the B cell population and causes 
unintended skewing of the CD11b expressing fractions. Other models of lupus which do 
not have a direct effect on B cells, such as ABIN1D485N, may reveal more about CD11b in 
disease progression.  
Preliminary experiments (data not shown) have demonstrated that CD11b 
expression or non-expression on plasma cells and mature B cells is conserved in vitro for 
up to 72 hours in stimulation conditions. This suggests that CD11b expression is not a 
transient property, is rather a long-term characteristic of these populations. Whether 
expression of this regulator is a germline-intrinsic property or something that can be 
induced remains to be seen. Additionally, the functional response of the CD11b+ and 
CD11b- populations of these subsets must be evaluated. Ongoing experiments comparing 
the BCR repertoire of the divergent CD11b subsets will reveal much about the functional 
impact of CD11b. It is anticipated that the CD11b+ will contain a higher frequency of 
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autoreactive BCR specificities, which would indicate CD11b expression is controlled by 
B cell negative selection; but this remains to be been. 
The identification of dynamic CD11b expression on novel B cell subsets provides 
the potential outline of a complex regulation mechanism for BCR signaling. Further 
experiments are necessary to understand the function and precise role of CD11b in these 

















Though the intended function of the immune system is to protect from foreign 
pathogens, genetic abnormalities and environmental factors can cause malfunction 
leading to pathological effects and damage to self, categorized as autoimmune disease. 
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by the 
degradation of B cell tolerance, leading to the production of antibodies against self-
antigens which cause severe inflammation in the joints and kidneys (206). Many different 
single nucleotide polymorphisms (SNPs) have been shown to contribute to SLE 
pathogenesis. One such SNP, rs1143679, causes a mutation in CD11b (207, 208). Herein, 
we will overview SLE as a disease and review the known impacts of CD11b mutation on 
disease outcome. 
Presentation and Causes of SLE  
 Modern study of SLE has revealed several different forms, presentations, and 
causes of the disease; however, a set of characteristic hallmark symptoms is shared 
among them. Cutaneous manifestations are nearly universal in SLE, appearing in over 
75% of patients, which can then be partitioned into lupus erythematosus-specific or non-
specific symptoms (209). The disease’s namesake results from an acute cutaneous lupus 
erythematosus (ACLE) that often occurs as a butterfly rash on the face, or as a more 
generalized maculopapular exanthema (210). Another SLE subset, discoid lupus 
erythematosus (DLE) is characterized by inflammatory plaques, follicular hyperkeratosis, 
and scarring leading to to recognizable patterns of hair loss (211). Over 90% of SLE 
patients also have musculoskeletal system involvement. Myalgia, arthralgia, and arthritis 
are the most common symptoms of this type (212). The central nervous system is 
affected in roughly 30% of SLE cases. However, the symptoms are very nonspecific, and 
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not reliable identifiers of the disease (213). Psychosis, depression, epileptic seizures, and 
transverse myelitis are among the peripheral neuropathies seen in SLE (214). 
 Though only 50% of SLE patients develop lupus nephritis (LN), it is one of the 
major causes of morbidity and hospitalization among all SLE manifestations (215). 
Because of the aggressive nature of renal involvement, the threshold for preforming a 
biopsy is somewhat low (216). Proteinuria and hematuria are standard signs of LN. 
Glomerular nephritis followed by subsequent chronic renal damage and kidney failure 
remain the classic pathological symptoms of LN.   
 The genetic component to SLE has long been established, as first seen in the 
heightened rate of the disease in monozygotic twins. Genes involving the major 
histocompatibility complex (MHC) were the first major loci found to associate with SLE. 
Many of the SNPs in this region remain among the most impactful on susceptibility 
(217). Genome-wide association studies have revealed a number of additional genes 
related to SLE and other immune disorders. They typically fall into one of three major 
mechanisms: Interferon (IFN) signaling, clearance of immune complexes and cellular 
waste, and lymphocyte signaling and activation (218). Some major lymphocyte activation 
gene loci involved in autoimmune disorders include PTPN22, IL-10, IL-21A, CD44, 
LYN, and IKZF2. A few IFN pathway loci of interest are PRDM1, IRF5, IRF7, and 
SOCS1. Lastly, relevant clearance genes comprise FCGR2A, FCGR2B, and CLEC16A 
(219). While these loci are ubiquitous to several immune disorders including SLE, many 
monogenic causes of SLE have been identified. Some of the more notable genes include 




Pathogenesis of SLE 
There are several different cell types and subsets implicated in the pathogenesis of 
SLE, and B cells are most predominately associated with the disease due to the large role 
of autoreactive antibodies, notably ANAs. These ANAs are the result of a break in 
tolerance of self-reactive B cells. The generation of hallmark ANAs in SLE first requires 
a breakage of B cells from one or more of tolerance pathways. Indeed, disfunction within 
the B cell itself has been associated with SLE more than other cell types. Risk-loci 
analyses revealed B cell genes mostly strongly correlated with SLE while alleles from 
memory T cells were implicated in rheumatoid arthritis, further cementing SLE as a B 
cell-centric disease (225). Many of these B cell defects disrupt the aforementioned 
tolerance mechanisms, leading to increased production of antibody regardless of antigen 
specificity. Combining this with the large fraction of immature B cells that are reactive to 
nuclear antigens creates the strong potential for the production of ANAs (226). 
Additionally, B cells may react to nuclear antigen without requiring BCR specificity 
through innate immune pathways (17). Defects in the B cell activation pathway may also 
contribute to the development of SLE, regardless of tolerance-induction. These 
mechanisms serve to regulate the strength and longevity of activation signals generated 
by BCR ligation, and their disruption can drive SLE (227). 
High-affinity effector IgG and chronic antibody responses in SLE result from 
plasma cells and long-lived memory B cells differentiated from the germinal center. In 
several lupus mouse models, enhancement of the GC reaction is a hallmark phenomenon 
(228). Human SLE patients display increased frequency of peripheral pre-GC B cells, Tfh 
cells, and memory B cells which are indicative of the GC reaction (229). These abnormal 
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GCs give rise to PCs and the production of pathogenic IgG antibodies through multiple 
apparatuses. Firstly, the entry of autoreactive naïve B cells into the GC can contribute to 
SLE. These cells are normally excluded from entering the B cell follicle and subsequent 
GC at a tolerogenic checkpoint that is not well understood (230, 231). Autoreactive B 
cells from SLE patients have been found to circumvent this mechanism entirely and 
proceed to the GC stage while non-SLE patient cells do not (232). Even if this tolerance 
checkpoint remains effective, non-autoreactive B cells may become self-reactive in the 
GC. The majority of pathogenic antibodies in SLE have undergone SHM. The large 
fraction of post-GC IgG autoreactive cells compared to the smaller amount on pre-GC 
autoreactive B cells suggests the autoreactive epitope is generated during the GC 
reaction. Autoreactive memory B cells have been shown to derive from this pathway, but 
the generation of autoreactive PCs via this mechanism is unproven (233-235). 
In SLE patients, the GC has increased survival that enables them to generate 
higher amounts of autoreactive PCs. Critical GC cytokine BAFF is markedly elevated in 
SLE patients (236). Increased amounts of BAFF not only encourages the survival of GC 
B cells that may otherwise fail selection checkpoints, but also promotes Tfh expansion. 
Activity of the Tfh cells is able to promote autoreactive GC B cells, and increased 
numbers of Tfh cells has been linked to SLE. Tfh cells produce IL-21, which has been 
shown to be critical in the development of self-reactive PCs and is increased in SLE 
patients (237, 238). OX40L expression on B cells is essential for Tfh maturation, and 
overexpression of B cell OX40L has been suggested to enhance the autoimmune response 
via Tfh expansion in some lupus mouse models (239). Mutations in OX40L have also 
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been associated with human SLE, further demonstrating a role for Tfh cells in the disease 
(240). 
CD11b Mutation rs1143679 and SLE 
A coding variant in ITGAM has been associated with incidence of SLE. Identified 
as rs1143679, this mutation results in an arginine to histidine amino acid substitution at 
the 77th position, described as R77H (119). This substitution is in the extracellular 
domain of the molecule, very near the primary ligand-binding portion. The change of a 
larger and more highly charged amino acid to a smaller, less drastically charged one near 
a crucial site has implications on the molecule’s function (124, 207). 
Studies have identified differences frequency of the rs1143679 variant across 
multiple populations. While other ITGAM variants exist, rs1143679 was found to be the 
most strongly associated with SLE across different groups. In one study, 17.2% of SLE 
patients of European ancestry possessed this variant, while only 10.4% of healthy 
subjects were carriers. For patients of African descent, frequency was slightly lower with 
15% incidence for the SLE group and 10% in healthy controls. Interestingly, analysis of 
the Gullah subpopulation of African descent found higher association with SLE at 20% 
disease incidence and 11% in controls (124). In a different study, Hong Kong Chinese 
and Thai populations were observed, finding only 1.1% and 6.2% SLE association, 
respectively. Healthy patient mutation frequency was expectedly lower at 0.51% and 
2.1% (241). An examination of Hispanic-Americans revealed a 17% SLE association and 
9% in controls (242). For a Northern Indian cohort, incidence was 14.3% for SLE 
patients and 8.7% in healthy individuals (243). These data demonstrate a varying range of 
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rs1143679 frequency among varied populations, with significant differences even in 
small sub-groups. 
The effects of this ITGAM variant have been examined in multiple cell types. 
Notably, total expression of CD11b is not altered in variant-carrying monocytes and 
neutrophils. Even CD11b activation via PMA did not affect expression, indicating the 
mutation does not alter inside-out signaling or functional expression. However, 
phagocytosis in these cells is impaired. Both ex-vivo variant macrophages and variant-
transfected macrophage cell lines demonstrate reduced phagocytosis via iC3b. Adherence 
assay revealed reduced binding to iC3b, ICAM1, DC-SIGN, and Fibrinogen in variant 
cells. Binding of CR3 inhibits release of TLR7/8 cytokine in healthy cells, but inhibition 
was lost in variant monocytes (207). This reveals a potential mechanism for rs1143679 in 
SLE pathogenesis via dysfunctional CD11b regulation of TLR7/8 activation in response 
to inert nuclear antigen (244). Supporting this, CD11b has also been shown to mediate C3 
activation of immunosuppression and tolerance in response to UV light damage, an 
established risk factor of SLE (245). Inflammatory cytokine production is normally 
inhibited by CD11b. Indeed, variant-expressing macrophage lines have much higher 
levels of IL-6 than control cells following stimulation, demonstrating yet another 
deficiency in proinflammatory cytokine regulation (246).  
The rs1143679 variant alters neutrophil function via Mac-1 disruption. In one 
study, primed variant-carrying neutrophils are shown to be deficient in phagocytosis of 
Mac-1 dependent opsonized particles, while several other phagocytosis receptor 
pathways are unaffected. Affected pathways included phagocytosis via the Fc receptor, 
which are less able to phagocytose IgG-coated particles than non-variant neutrophils. The 
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same report also demonstrates reduced firm adhesion by variant neutrophils (247). 
Variant deficiency in adhesion has been examined in-depth, revealing a non-binding 
regulatory role of the R77 region of CD11b. Under tensile force conditions, the R77 
contributes to brief-catch bond stability of the binding region, allowing disassociation of 
the cytoplasmic tail domain of the alpha subunit from the beta subunit in binding 
conditions. The R77H variant causes accelerated formation of these catch-bonds, leading 
to non-disassociation of the cytoplasmic domains and prolonging the Mac-1 complex-
ligand binding lifetime (248). The complexities of these structural interactions are still 
largely unknown and must be investigated further to better understand how this variant 
leads to disease susceptibility at a systemic level. 
As stated above, total expression of CD11b was altered by the rs1143679 variant 
expressed in cell lines. However, Maiti et al. have shown a dose-dependent change in 
CD11b expression in SLE patients depending on risk allele transcripts. Patients 
homozygous for the variant had reduced CD11b expression on peripheral blood 
mononuclear cells (PBMCs) at both the surface and RNA expression levels compared to 
heterozygous patients. Within the heterozygous cohort, they also identified differences in 
expression and regulation of the variant versus non-variant forms of CD11b. Strikingly, 
expression of the non-variant form was seven times higher than the variant. This was 
found to be an effect of a damaged transcriptional enhancer region in the rs1143679 
variant allele (249). These findings demonstrate the crucial protective effect of a single 
copy of the non-variant form of CD11b and suggests a reason for the common prevalence 
of the variant in healthy patients despite the strong association with SLE. However, a 
recent report by Roberts et al. directly contradicts these data, suggesting that monocyte 
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and NK cell expression of CD11b is not altered by rs1143679 in any way. Their results 
found no difference in CD11b expression between  homozygous, heterozygous, and non-
variant genotype groups in classical monocytes, non-classical monocytes, CD16 
expressing monocytes, and four NK subsets (250). These opposing publications 
exemplify the current lack of understanding of the role of rs1143679 and the necessity for 
further investigation of this variant form of CD11b. 
Association studies have found a number of disease trends in rs1143679 carrying 
SLE patients. This ITGAM variant, as well as others, are associated with elevated IFN-I 
activity in SLE. Cells from these subjects also had increased expression of IFNB and 
IRF7 transcripts, suggesting a potential pathway for type-1 IFN production (251). Other 
proinflammatory cytokines IL-6, TNF-α, and IL-1β are higher in SLE patients with this 
variant as well (207, 252). The same group of ITGAM variants has also been associated 
with anti-dsDNA autoantibody (253). In some SLE populations, the R77H variant is 
linked to higher levels of antiphospholipid antibody (254). Though this variant has been 
associated with SLE in multiple studies, more recent data has found that this and other 
ITGAM risk alleles are much more strongly associated in patients with renal nephritis 
than those without. The same trend has been shown in SLE patients with neurological 
disorders (241). This association of rs1143679 with more severe disease phenotype 
further supports the function of CD11b as a key regulator. 
Due to the prevalence of rs1143679, the Mac-1 receptor/CD11b has become a 
potential therapeutic target for treatment of SLE. In one study, CD11b agonist 
leukadherin-1 (LA1) was able to reduce kidney neutrophil influx and proteinuria in an 
inducible nephritis mouse model (255). The same treatment can also reduce production of 
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proinflammatory cytokines IL-1β and IL-6 in neutrophil and macrophages (251). LA1 
has been tested in the MRL/lpr lupus model as well. Here, administration of the small 
molecule resulted in reduced IFN-I responses, partial integrin activation, and protection 
from organ injury (251). The emerging use of CD11b agonist as a therapeutic shows 
promise, but the expression of ITGAM across multiple cell types exposes a number of 
potential off-target effects in humans. A better understanding of CD11b function in 
individual cell types is necessary to develop more highly specific treatments able to target 
the pathogenic involvement of this pathway in SLE. 
 Though B cells play a central role in SLE, the relationship of B cell function and 
mutation in ITGAM is poorly defined. Our previous work has revealed CD11b as a novel 
regulator of BCR signaling and B cell activation, suggesting the presence of a B cell-
intrinsic defect caused by ITGAM mutation in rs1143679 expressing SLE patients. 
Indeed, a human B cell line expressing this mutant form was found to have defects in 
negative regulation of the BCR signaling pathway (136). However, the functional impact 
of this mutation in primary B cells from SLE patients has not been examined. In the 
following study, we examine the prevalence of rs1143679 in nephritic SLE patients in the 
Louisville region and attempt to correlate its incidence to clinical outcome. We also 




MATERIALS AND METHODS 
Immunizations and Ab Detection 
Human and anti-dsDNA antibody was detected using respective anti-dsDNA ELISA kits 
(Signosis Inc). Antinuclear antibody (ANA) was detected using HEp-2-coated antigen 
substrate slides and confocal microscopy (MBL International). 
 
Antibodies, Flow Cytometry, and Cell Sorting 
Single-cell suspensions of PBMCs were treated with Fc-blocker for 10 minutes on ice 
followed by staining with appropriate fluorochrome-labeled antibody or isotype controls 
for at least 20 minutes at 4°C. Cells were then washed with 10 volumes of PBS before 
resuspension in PBS for acquisition or Running Buffer (Miltenyi Biotech) for sorting. 
Flow cytometry samples were acquired using a FACSCanto cytometer (BD Biosciences) 
and analyzed using FlowJo software (Tree Star). Sorting was performed using FACSAria 
III (BD Biosciences). Cell purity was confirmed at greater than 90% via flow cytometry. 
The following anti-human antibodies were used: fixable viability dye (eBioscience), 
human Fc-blocker, CD10, CD19, CD24, CD27, CD38, IgD (Biolegend).  
 
Human Subject Samples 
SLE patient blood was obtained from the University of Louisville Nephrology 
Department in collaboration with Dr. Dawn Caster and Dr. Kenneth McLeish. The study 
was approved by the Institution Ethical Board and blood samples were collected upon a 
written informed consent. Patient SLE classification varied on a case-by-case basis, as 
did time since first diagnosis. Blood samples were obtained immediately following draw 
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for processing. Whole blood cells were frozen in -80°C for DNA isolation. Plasma was 
obtained via centrifugation and frozen in aliquots at -80°C. PBMCs and Neutrophils were 
purified from remaining blood with a dual-histopaque density gradient. PBMCs were 
gradually frozen in freezing buffer (90% FBS, 10% DMSO) at -140°C. Neutrophils were 
frozen in TRIzol at -80°C for RNA extraction. 
 
Genotyping of ITGAM R77H rs1143679 
DNA was extracted from 100μL of whole blood using a Blood & Cell Culture DNA 
Maxi Kit (Qiagen). The presence of rs1143679 was identified via PCR and carried out 
with the following primers: 5’-CTGGTTTTTGTGTCATTCTTAGG-3’; 5’-
GAATCCCAGTCCCAGCCCG-3’. PCR products were then subjected to enzymatic 
digestion with endonuclease SsiL(C/CGC) (Thermo Fisher Scientific) before 
electrophoresis on a 2% agarose gel. The ITGAM 77R allele was cleaved into 304, 24, 
and 22 base pair fragments. The 77H allele was cleaved into 328 and 22 base pair 
fragments. 
 
Hunan Plasmablast Culture 
Frozen whole PBMCs were thawed and counted. Cells were labeled with 
Carboxyfluorescein succinimidyl ester (CFSE) and washed. Whole-labeled PBMCs were 
cultured in a 96 well plate at 2.5 x 106 cells/mL in the presence of 10μg/mL anti-IgM, 
0.33nM CpG, and 20ng/mL hIL-21 for 7 days. Upon well harvest, cells were used for 




Statistical Analysis  
All quantitative data are shown as mean± s.e.m unless otherwise indicated. All samples 
were compared using two-tailed, unpaired Student’s t test. A p value less than 0.05 was 





A phenotypic survey of ITGAM mutation rs1143679 in SLE patients of the 
Louisville region. 
 The ITGAM mutation rs1143679 has been observed in multiple populations and 
ethnicities in many different countries, as previously discussed. We sought to examine 
this polymorphism in SLE patients within the Louisville, Kentucky region of the United 
States. Peripheral blood was collected from consenting SLE patient donors in care of the 
University of Louisville’s nephrology clinic at varying ranges of age, disease state, 
treatment regimen, and time since diagnosis. Clinical diagnostic data was also provided. 
 We first performed genotyping for the R77H allele using whole blood. From a 
cohort of 38 patients, we identified 11 (28.95%) patients homozygous for rs1143679 
(described as HH) while 18 (47.37%) and 8 (21.05%) were heterozygous (RH) or non-
carriers (RR), respectively (Figure 34). A single patient carried an unknown SNP, 
identified by irregular PCR results. The incidence of the homozygous mutation is slightly 
higher than that of all other previously reported groups, though this may be due to 
variation in the low (relatively) sample size. Expectedly, the majority of patients (97.4%) 
were female, thus no sex correlation could be investigated. Roughly 75% of patients were 
African American and 25% were Caucasian, both of which had the same incidence of 
homozygous R77H (Figure 35). Surprisingly, and contrary to previously reports, we 
found no correlation in severity of lupus nephritis with homozygous rs1143679 mutation 
(254, 256, 257). There was a slight, but non-significant, increase in the age of onset for 
carriers, averaging at 6.5 years. The frequency of joint and skin involvement was 
consistent among the groups, a roughly 82% and 62%, respectively. Serum levels of C3 
and C3 were also unaffected by ITGAM mutation. Level of anti-dsDNA IgG antibody 
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did appear to increase with rs1143679 incidence, though this association was not 
statistically significant. Interestingly, there was a trending increase in serum creatine 
levels in homozygous and heterozygous carriers, but not in protein/creatine ratio.  
 We next preformed a panel staining on patient PBMCs to examine the effect of 
ITGAM mutation on the frequency of several B cell subsets. Our panel identified the 
transitional 1, transitional 2, mature naïve, plasmablast, non-switched memory, and 
double-negative memory B cell populations (Figure 36). Surprisingly, we did not observe 
any significant correlation in these populations with incidence of rs1143679 (Figure 37).  
 To examine the functionality of the B cells from these three groups, we cultured 
PBMCs in vitro in the presence of BCR, TLR9, and IL-21r stimulation to induce 
plasmablast differentiation. Among the three genotype cohorts, we observed no 
significant alteration the ability of these B cells to differentiate (Figure 38). We also 
found no impact of R77H mutation on the amount of ANA and anti-dsDNA antibody 
produced. 
 These summary data demonstrate no strong correlation of clinical outcome with 
homozygous or heterozygous ITGAM mutation. Combined with the lack of functional 
alteration in our in vitro assay, it appears rs1143679 does not cause a significant impact 





Figure 34: Incidence of rs1143679 in Louisville, KY area SLE Patients. Whole blood 
was obtained from SLE patients at the University of Louisville’s Nephrology Clinic. 
DNA was extracted, and PCR was performed for the rs1134679 allele, as described in the 
methods section. Example PCR results (top) and the incidence of R77H alleles in the 
cohort (bottom) are shown. A 304 base-pair band indicates the normal allele “R”, while a 





Figure 35: Clinical and demographic associations of rs1143679 in SLE. Clinical data 
from patients homozygous for mutant allele (HH, red) were compared with patients 
carrying a single copy (RH, yellow) or no mutation (RR, blue). *P<0.05 (unpaired two-





Figure 36: Identification of peripheral B cell subsets in SLE patients. Purified 
PBMCs from SLE patients were stained with antibody to identify B cell subsets. All 
populations were gated on CD19+ and identified as follows. Plasmablasts: CD38+ CD27+, 
non-switched memory: CD27+ IgD+, double-negative memory: CD27- IgD-, Mature 
Naïve: IgD+ CD27- CD24+ CD10-, Transitional 1: IgD+ CD27- CD24hiCD10-, Transitional 





Figure 37: Peripheral B cell subsets in SLE patients with ITGAM mutation. Purified 
PBMCs from SLE patients were stained with antibody to identify B cell subsets, as 






Figure 38: In vitro differentiation of plasmablasts from SLE patient PBMCs. Whole 
PBMCs from SLE patients were labeled with carboxyfluorescein succinimidyl ester 
(CFSE) and cultured in the presence of 10μg/mL anti-IgM, 0.33nM CpG, and 20ng/mL 
hIL-21 for 7 days. Cells were stained with CD19, CD27, and CD38 to identify 
plasmablasts, B cell-blasts, and mature naïve cells as shown. CFSE signal was used to 
determine proliferation of the plasmablast population. Anti-dsDNA antibody and ANAs 
from the supernatant were measured via ELISA and microscopy score, respectively, 




The link between ITGAM mutations and SLE has been long-established. Previous 
research has focused on the impact of this mutation on the function of hallmark CD11b 
expressing cells.  Indeed, these studies have found macrophage and dendritic cells 
carrying the R77H form of CD11b have defects in phagocytosis, which is thought to 
contribute to SLE via the buildup of autoreactive antigen. However, our identification of 
CD11b as a BCR regulator has revealed B cells as a potential contributor to SLE 
pathogenesis in carriers of this mutation. 
In our SLE cohort, we found a surprisingly high incidence of homozygous 
rs1143679 at nearly 29%.  Previous studies have found 20% incidence in people of 
African descent, while European ancestry was at 17% (124). 23% of our African 
American patients carried the HH allele, while Caucasian patients had 33% incidence. 
However, this unusually high rate is likely due to a small sample size of 9 Caucasian 
patients. The prevalence of heterozygous carriers at 47% incidence was surprising, 
though the single mutant allele is unlikely to have any disease impact as previous work 
has found one functional gene provides a protective effect in neutrophils (247). 
Association of ITGAM mutation and incidence of LN in Hong Kong Chinese, 
Thai, European, African American, and Latin American ancestry populations has 
previously been identified (254, 256-258). Our SLE cohort was unintentionally pre-
selected for LN, as all patients were recruited via a nephrology clinic. Therefore, no such 
correlation could be examined. However, we were able to compare LN severity among 
R77H groups. Homozygous carriers and non-mutants had nearly equal numbers of 
patients with class 3, 4, and 5 nephritis. The heterozygous group had a proportionally 
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higher amount of class 4 nephritis, but this is likely coincidental since the mutation is 
recessive, as discussed earlier. The association of ITGAM mutation with incidence, but 
not severity, of LN in SLE suggests an involvement in the initiation of kidney disease. 
We were able to detect a slight increase in the anti-dsDNA IgG titer of rs1143679 
patients, which has also been reported before (256). Perhaps higher amounts of self-
reactive antibody, resulting from increased B cell activity and decreased myeloid 
phagocytosis of nuclear antigen due to ITGAM dysfunction, is promoting a break in 
tolerance and initiation of kidney disease. The age of onset, incidence of joint 
involvement, and incidence of skin symptoms all showed no R77H correlation, similar to 
previous studies (259). Although CD11b functions as party of complement receptor 3 
(CR3), no association of rs1143679 with C3 or C4 levels was found in our study or work 
by others (260). Reduction in C3 and C4 levels is a known indicator of SLE disease 
activity, but it appears they are not dependent on ITGAM function (261). Serum creatine 
levels were slightly increased in homozygous patients, but the creatine/urine protein ratio 
was not. Creatine is a classic biomarker of overall lupus severity, while the creatine/urine 
protein ratio is more specific to LN (262). It is possible that rs1143679 carriers do 
develop more server disease, but pre-selection for LN obscures and trend in the 
creatine/urine protein ratio. Our study was unable to reveal any novel correlations; thus, a 
larger cohort and a more comprehensive study of clinical biometrics may be required to 
better examine the effect of rs1143679 in LN and SLE. 
Examination of the peripheral B cell subsets of our patient cohort surprisingly did 
not reveal any substantial association with ITGAM mutation. Pre-activation populations 
of transitional 1, transitional 2, and mature naïve B cells are likely upstream of any 
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alteration of BCR activation caused by ITGAM dysfunction, and thus are unaffected. The 
lack of correlation in late stage memory B cells and plasmablasts with rs1143679 
suggests that CD11b signaling alone is not enough to control disease. Indeed, our in vitro 
assays were also unable to produce a significant relationship of B cell response to this 
mutation. However, two major factors may be obscuring these results. Firstly, our cohort 
is both small in size and largely variable, most notably in the current disease treatment 
patients are under at the time of sample draw. Patients are receiving a wide range of 
different treatments, which can heavily influence the peripheral B cell populations. Our in 
vitro studies attempted to negate this effect by “washing out” any present drug influence, 
but the pre-selection of the B cell population by months or years of immunosuppression 
may have too large of an impact. Secondly, previous work has correlated rs1143679 with 
higher incidence of LN, but all of our patients were recruited via a nephrology clinic and 
thus were pre-selected with some amount of renal involvement. This screening of our 
patient population could be heavily skewing any correlation with clinical data or 
outcomes. The addition of an equal sized, non-nephritic cohort would allow for better 

















Much of the modern study of the immune system is focused on the identification 
and investigation of cell regulatory pathways. Treatments such as cancer immunotherapy, 
targeted immunosuppression, and the booming field of personalized medicine have all 
arisen from the discovery of novel immunoregulatory mechanisms that can be exploited 
to produce a favorable disease outcome. As the gaps in conventional knowledge become 
filled in, we must examine the unconventional and unexpected to further our 
understanding of immune system function.
 
 
Despite the identification of CD11b expressing B cell subsets over 25 years ago, 
its function in these cells has gone largely ignored. Classically considered a marker of 
myeloid cells, this low-key B cell population was passed over in favor of targets with 
more obvious potential. Previous findings showed the importance of CD11b in 
controlling autoimmunity and identified a functional role in B cells. In this study, we 
expanded this knowledge by demonstrating that CD11b acts as a controller of the healthy 
B cell response by regulating BCR activation signaling, therefore controlling the 
downstream generation of effector B cell subsets and immunogenic antibody. The ability 
lowly-expressed molecule to cause such a dramatic shift in response suggests either a 
potent ongoing regulatory effect, or acute regulation at a critical stage. Indeed, 
association of CD11b regulation with the CD22-Lyn-SHP1 circuit implicates 
participation in multiple regulatory mechanisms rather than restriction to a single 
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pathway. It would be of interest to determine if there are stimulatory conditions, such as 
the presence of specific cytokines or certain types/sources of antigen, in which CD11b-
dependent regulation is ignored or disabled. Additionally, the actual mechanism of 
CD11b’s regulatory effect is still unknown. The strong association of CD11b with CD22 
suggests a critical stabilizing interaction which allows recruitment of SHP-1 and Lyn. 
Confirming whether this is through direct binding or is mediated through other molecules 
could reveal additional therapeutic targets of this mechanism. 
 The revelation of dynamic CD11b expression across B cell development implies 
an ability of these cells to control BCR regulation on a contextual basis. The inverse 
patterns of lowered and elevated CD11b expression following immunization in respective 
long-lived and short-term effector B cell subsets implies great complexities in not only 
CD11b control of BCR signaling, but cellular control of CD11b expression. It will be of 
great importance to determine precisely what factors are controlling the expression of 
CD11b, and whether they are shared among these divergent subset groups. The influence 
of different autoimmune models on CD11b in these cells is also very telling. Highly 
differential patterns between the Faslpr and ABIN1 models of lupus hints at an association 
of CD11b with autoreactive cell selection. Expression of this regulator may be relevant in 
the context of other diseases as well, and warrants pursuit. 
 Of particular note is the how many of the newly identified CD11b expressing B 
cell subsets are a relatively small fraction of the whole population. Most of these CD11b+ 
sub-populations are less than 10% of the total cell type; however, they are distinctly 
defined by high CD11b instead of a low to intermediate level of expression.  Several of 
our ex vivo experiments with CD11b knockout models have revealed defects in the entire 
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B cell and GC B cell populations, clearly impacting a larger portion of cells than the 
small fractions identified in our reporter system. Determining whether these well-defined, 
higher CD11b expressing populations function differently than those with lower levels 
will reveal much about its role in controlling autoimmunity. Preliminary experiments 
have indicated this level of CD11b expression is indeed a permanent feature of these 
cells, rather than a transient shift amongst the entire B cell population. Indeed, ongoing 
studies to compare the repertoire of these defined CD11b expressing and non-expressing 
populations are currently underway. These studies can reveal a potential association of 
CD11b expression level with BCR specificity or self-reactivity. 
 Though our clinical research was not able to identify any novel correlations of 
ITGAM mutation with disease outcome or cell function, a more powerful study may be 
able to better answer these questions. In particular, examining the function of B cells 
from rs1134679 carrying healthy individuals would provide insights into the impact of 
CD11b function without the influence of disease state or long-term immunosuppressive 
treatment seen in our SLE cohort. It will also be vital to assess the expression pattern of 
CD11b in human B cell subsets, to determine the similarity to mouse models and the 
efficacy of their use. As part of our ongoing work, we will compare the peripheral B cell 
repertoire of ITGAM-variant and non-variant SLE patients, which can provide new 
insights on the impact of CD11b in B cell selection during disease.  
 In conclusion, these findings have confirmed the B cell-intrinsic effects of CD11b 
regulation on the humoral immune response and revealed the potential for dynamic 
functions of regulation across different stages of B cell maturity. Further research is 
necessary to delineate the exact purpose, mechanism of action, and impact of this 
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regulation within each subset. The contribution of these regulatory processes to overall 
immune health can provide insight into the role B cell CD11b plays in human disease, 













TRANSCRIPTION FACTOR STAT3 SERVES AS A NEGATIVE REGULATOR 
CONTROLLING IGE CLASS SWITCHING IN MICE1  
                                                          
1 This work has been accepted for publication in the following: Dascani et al “Transcription Factor STAT3 




Production of the appropriate antibody class is a vital function of the B cell 
immune response. Immunoglobulin E (IgE) is likened with defense against parasitic 
infections (263). IgE is also largely associated with hypersensitivity and allergic disorders 
(264). Hyper IgE syndromes (HIES) are a group of immune disorders characterized by 
specific infectious susceptibilities, eosinophilia, and extremely high levels of IgE class 
antibody in the serum (265). Incidence of HIES has been linked to heterozygous 
mutations in the signal transducer and activator of transcription 3 (STAT3) gene (266, 
267). However, precisely how transcription factor STAT3 contributes to the hyper-IgE 
phenotype has not been fully understood. 
Class switching primarily occurs in the GC. In this unique microenvironment, 
recently activated B cells undergo class switch recombination and somatic hypermutation 
(SHM) to produce plasma cells which secrete high-affinity antibodies (268). STAT3 is 
well established as a major regulator of lymphocyte function, acting downstream of vital 
GC-related cytokines such as IL-4, IL-10, and IL-21 (269, 270). It has also been 
implicated as a critical factor for the development of T helper 2 (Th2) cells as well as 
follicular helper T cells, which are an essential component of the GC reaction (271, 272). 
Studies using B cells from STAT3 loss of function HIES patients have revealed 
defects in many downstream effects of IL-21 and IL-10, including differentiation of 
antibody secreting cells (273, 274). Interestingly, these cells also demonstrate no 
alteration in their ability to class switch to IgM, IgG, and IgA forms (275). Reduced 
responses to vaccination and diminished memory B cell generation in these patients 
further suggests an important role for B cell function and antibody production (276). 
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Despite these extensive findings, how exactly STAT3 controls IgE class switching 
remains largely unaddressed. 
Hyper IgE Syndrome 
 Elevated level of immunoglobulin is a hallmark trait of several autoimmune 
disorders. In many of these diseases, such as SLE, effector IgG class antibody is the 
primary cause of pathogenicity. However, there are also many primary 
immunodeficiencies characterized by elevated levels of serum IgE, termed Hyper IgE 
Syndromes (277). HIES are often hallmarked by frequent and reoccurring infection of the 
lungs and skin by staphylococcus and fungal sources, as well as eczema and eosinophilia 
(278). 
The study of this group of diseases has identified mutations in JAK-STAT 
molecules as the primary cause, attributing specific mutations to unique forms of the 
disorder. Autosomal-recessive (AR) forms of HIES are most often caused by null 
mutations in DOCK8, a GTPase activator (279). Though much less frequent, defects in 
PGM3 and TYK2 have also been linked to AR-HIES (280, 281). Interestingly, despite 
their similar functions, these different mutations cause distinct disease phenotypes. 
Patients with DOCK8 deficiency often have more severe mycobacterial and viral 
infections, whereas PGM3 is more strongly associated with neurocognitive symptoms 
(282). 
Autosomal dominant (AD) HIES is the most common and well-studied form of 
hyper-IgE diseases. Also known as Job’s syndrome, AD-HIES was first described in 
1966 by Davis et al. and identified by its hallmark eosinophilia, eczema, and recurring 
infections (278). The namesake elevated serum IgE was then identified by Buckley et al, 
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coining the term HIES (283). Modern studies have since described these symptoms in 
more detail. Eczematoid rashes manifest only weeks after birth, usually around the scalp 
and face (284). Biopsy of these rashes reveals a Staphylococcus aureus driven 
eosinophilia, which can be resolved with antistaphylococcal therapy (285). Elevated 
serum IgE is also identified at their early stage, with titers of at least 2,000 IU/mL, if not 
higher (286). Recurring sinus and pulmonary infections can begin at 2-3 months of age, 
caused most frequently by S. aureus. These events can lead to permanent parenchymal 
lung damage and dangerous secondary infections that are a high source of morbidity and 
mortality in AD-HIES patients (287, 288). Patients are also susceptible to nonfilamentous 
molds such as pneumocystis jioveci leading to pneumonia, or cryptococcus in the 
intestine (289, 290). 
In addition to these immunological symptoms, AD-HIES is also associated with 
manifestations involving dental, musculoskeletal, neurological, and vascular pathologies 
(291). In late childhood, facial patterns of asymmetry and coarse skin can be observed. 
Osteopenia and severe scoliosis may occur and require intense treatment (292). 
Abnormalities of the oral cavity are very common, as is failure to shed primary teeth 
without surgical intervention (293). Coronary artery aneurism is found in over 70% of 
AD-HIES patients, as was hypertension (294). Lastly, T2 hypersensitivity of the central 
nervous system are a common but poorly understood occurrence in this disease, and is 
often used as a diagnostic measure (295). 
 Despite a half-century of study, the genetic origin of AD-HIES was not identified 
until 2007 by Holland et al (296). This report examined a large cohort of AD-HIES 
patients found missense mutations in the SH2 and DNA-binding domains of STAT3. 
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Notably, the mutations were autosomal dominant, thus establishing the unique AD-HIES 
form of hyper IgE syndrome. STAT3 expression was equal among mutant and wild-type 
forms, as was the ability of the molecule to phosphorylate and translocate to the nucleus 
(297). Since these initial studies, new findings have found that mutations specific to the 
SH2 domain do decrease the ability of STAT3 to phosphorylate at Tyrosine 705 (298). 
Despite these advances, the overall mechanism behind how these mutations impair 
STAT3 function has not been elucidated, particularly for polymorphisms to the DNA 
binding region. However, a recent study by Bocchini et al. has revealed that stabilization 
via increase chaperone protein activity is able to improve STAT3 function (299). This 
suggests a defect in post-activation stability is the mechanism behind STAT3’s role in 
AD-HIES pathogenesis, but this warrant further investigation. 
STAT3 Signaling 
 STAT3 was initially discovered and characterized by its ability to bind and 
control transcription of the IL-6 promoter region (300). Since then, the function of 
STAT3 as well as other STAT-family transcription factors has been well documented. 
STAT proteins are strongly associated with the Janus kinase-signal transducers (JAK) 
family signaling molecules. These JAK-STAT pathways are vital to many growth factor 
and cytokine signals which control a wide array of cell functions from proliferation and 
differentiation to survival and apoptosis (301, 302). Indeed, defects in these JAK-STAT 
signaling pathways are associated with multiple forms of autoimmune disorder and 
cancer. 
 The specific mechanisms of JAK-STAT signaling varies for each individual 
molecule, but the general cascade of events is conserved. The binding of surface receptor 
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with extracellular ligand, such as a cytokine, causes dimerization of these receptor units. 
This event causes phosphorylation of the receptor cytoplasmic domain and subsequent 
recruitment of JAK proteins or induces phosphorylation of already present JAK 
molecules (303). The now activated JAK proteins then recruit and phosphorylate 
members of the STAT family in as homo or heterodimers, after which they translocate to 
the nucleus and activate target genes. STAT3 in particular is recruited by JAK1, JAK2, 
and TYK2 via phosphorylation on Tyrosine 705 (301).  
 As previously mentioned, STAT3 was first identified for its regulation of IL-6. 
Many more targets and activators of STAT3 have since been found. Some of the major 
cytokine activators of STAT3 include IL-6, IL-10, IL11-, IL-17, IL-21, and IL-22 (277). 
Downstream, STAT3 regulates an even greater array of genes including activation of IL-
6, IL-22, IL-26, IL17A, TGF-β, and MCP-1, and downregulation of TNF-α, IL-12, and 
IFN-γ (273, 277, 304, 305). These signals are involved in a widely diverse set of cell 
functions, including both pro and anti-inflammatory responses. Indeed, STAT3 
deficiency has been shown to impact both of these opposing forces in disease settings 
(306, 307). 
 Since it was first identified, much progress has been made on understanding the 
contribution of STAT3 deficiency to AD-HIES pathogenesis. Susceptibility to infection 
has been attributed to defects in the acute response driven by IL-6 (308). Likewise, 
defective IL-22 signaling can impair epithelial cell barriers which contributes to this 
effect (309). STAT3 mutations have also been shown to cripple the Th17 response, 
impacting CD4 T cell differentiation and neutrophil proliferation and chemotaxis. These 
deficiencies contribute to the reoccurring skin and lung infections in AD-HIES (310, 
129 
 
311). On the anti-inflammatory side, mutations in STAT3 compromise its role in IL-10 
signaling, resulting in increased inflammation in patients (312). 
 Predictably, antibody producing B cells are altered by STAT3 mutation in AD-
HIES, with the most obvious effect being increased production of IgE class antibody. 
Increased frequency of naïve and transitional B cells has also been noted in AD-HIES 
patients, along with decreased memory B cells (313). Surprisingly, T cells seem to be 
unaffected, implying the STAT3 driven B cell defect is not reliant on T cell help (314). In 
mice, loss IL-21 receptor, which utilizes STAT3, has been shown cooperate with IL-4 to  
negatively regulate production of IgE (315). Conversely, human studies have implicated 
IL-21 as an IgE inducer (316). Despite this obvious correlation with B cell IgE 
production, the specific relation and mechanism of STAT3 defects in regulating IgE 
antibody has not been previously studied. 
B Cell IgE Class Switching 
 Upon engagement with cognate antigen, naïve B cells can enter the GC reaction 
to proliferate, increase affinity via SHM, and differentiate into antibody producing PCs; 
all of which were discussed in the previous chapter. Another vital process of the GC is 
class switch recombination. In CSR, B cells alter expression of the constant region of the 
immunoglobulin heavy chain (IgH) locus which defines the class of antibody produced. 
Located 3’ from the variable VH, DH, and JH loci is the CH gene, comprised of multiple 
exons which each encode a different antibody constant region specific for an individual 
Ig class (317). Neighboring the upstream VJ exon is the Cμ exon which encodes the 
“baseline” IgM class, while downstream lie the Cα, Cε, and Cγ regions which encode the 
IgA, IgE, and IgG classes, respectively. Utilizing activation induced cytidine deaminase, 
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the same enzyme used for SHM, GC B cells edit the germline to replace the default Cμ 
exon with one of the downstream regions, causing class switching (318). 
 Structure of the constant region of an antibody, determined by the germline, 
significantly impacts antigen affinity, and each class is utilized for specific types of 
antigen. Because of this, B cells class switching to each of the effector types is regulated 
to respond appropriately to immune insults. The IgE class results from the Th2 immune 
response, and is believed to have evolved to protect against parasite infections (319). Th2 
type cytokines such as IL-4 and IL-13 have been shown to induce IgE class switching 
(320). Downstream of the cytokine receptor, STAT6 has been identified as a direct 
regulator of the IgE promoter, Iε. Acting as a homodimer, STAT6 coordinates promoter 
binding with other factors such as NF-κB, which can be induced by CD40-CD40L co-
signaling or TLR stimulation (321). 
Transcription of Iε requires the presence of E2A proteins at the promoter region. 
However, expression of E2A is negatively regulated by Id2, which is constitutively 
activated under resting conditions. This mechanism serves to restrict IgE class switching 
and maintain typical low levels (compared to other antibody classes) of serum IgE (322). 
Interestingly, master GC regulator Bcl6 also negatively regulates IgE class switching by 
blocking the Iε promoter (323). Despite the GC’s role as the driver of class switching, the 
IgE form is negatively controlled by its most important regulator. This further 
emphasizes how tightly controlled the production of IgE antibody is. Several other 
molecules have been found to bind the Iε promoter. AP-1 coordinates with STAT6 to 
initiate Iε transcription (324). Nuclear factor interleukin-3 (NFIL3) has been found to 
increase IgE class switching. Induced by IL-4, NFIL3 binds directly to the Iε promoter, 
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and mice lacking this molecule demonstrate severely reduced IgE production (325). 
However, upstream regulation of NFIL3 expression, beyond IL-4 signaling, is still not 
understood. 
IgE class switching is unique in that there are two pathways through with B cells 
can commit to this fate; direct and sequential switching. Direct switching is the traditional 
method, in which AICDA driven recombination removes loci upstream of Iε in a single 
step and causes its expression. In sequential switching, B cells first undergo a class 
switch to IgG1 via expression of the Iγ1 promoter. Then, during a second round of CSR, 
the gene is edited again to express the downstream Iε which was not removed in the first 
step. This has been identified via the presence of Iγ1 remnants present in IgE expressing 
B cells (326). More recently, it was shown that this sequential switch pathway is able to 
produce might higher affinity antibody than direct switching (327). These higher affinity 
IgE producing B cells may have a greater contribution to autoimmune disease than their 
lower affinity, direct switched counterparts. 
Notably missing from these known contributors to IgE class switching is STAT3. 
The well documented link between STAT3 mutation and AD-HIES establishes a clear 
role for this transcription factor in control of IgE, but this relationship has not been 
investigated. In this work, we seek to characterize the importance of STAT3 as an IgE 







MATERIALS AND METHODS 
Mice 
C57BL/6 T and/or B cell STAT3 conditional knockout (cKO) mice (STAT3fl/flCD2Cre/+ 
and STAT3fl/flCD19Cre/+) were generated by interbreeding STAT3fl/fl mice (328) (control) 
with CD2Cre/Cre or CD19Cre/Cre mice (The Jackson Laboratory), respectively. Mice at 6–8 
weeks of age with both sexes were used for experiments. All mice were housed and bred 
in a conventional facility at the University of Louisville. Animal care and experiments 
were conducted in accordance with the National Institutes of Health guidelines and were 
approved by the Institutional Animal Care and Use Committee at the University of 
Louisville. 
 
Immunizations and Ab Detection 
STAT3 control or cKO mice were immunized by i.p. injection with 100 µg of OVA in 
Alum adjuvant at a 1:1 ratio. Sera was collected before and at given time points after 
immunization. Anti-OVA antibody titers were measured via enzyme-linked 
immunosorbent assay (ELISA) using a 96-well plate coated with 1µg of OVA and a 
standard ELISAMAX kit (Biolegend, San Diego, CA). For IgE affinity detection, mice 
were immunized with NP23-CGG (Biosearch Technologies, Petaluma, CA). Sera was 
collected at day 14 post immunization. Anti-NP antibody was measured using parallel 
ELISAs in which wells were coated with 1µg of NP23-BSA or NP2-BSA. The OD value 
ratio was used to determine overall affinity. 
 
Abs and Flow Cytometry 
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Fluorochrome-labeled mAbs against IgG1, IgE, B220, GL7, CD138, and viability 
detection antibody were purchased from BioLegend (San Diego, CA). Single-cell 
suspensions were blocked in the presence of anti-CD16/32 and purified anti-IgE at 4°C 
for 15 minutes and stained on ice with appropriate Abs and isotype controls. For 
intracellular staining, cells were fixed and permeabilized followed by the addition of 
fluorochrome-labeled anti-IgE. Samples were acquired using a FACSCanto cytometer 
(BD Biosciences, San Jose, CA) and analyzed using FlowJo software (Tree Star, 
Ashaland, OR). 
 
Quantitative real-time PCR 
Splenic or iGB culture  GC B cells and plasma cells were sorted by FACSAria III. Total 
RNA was prepared with TRIzol (Life Technologies) and RNeasy mini kit (Qiagen, 
Valencia, CA). After reverse transcription into cDNA with a reverse transcription kit 
(Bio-Rad, Hercules, CA), quantitative PCR was then performed on a Bio-rad MyiQ 
single-color RT-PCR detection system using SYBR Green Supermix (Bio-Rad). Primer 
sequences are listed in Supplemental Table 1. Gene expression was normalized to the β2-
microblobulin (β-MG) housekeeping gene and represented data as the fold differences by 
the 2-ΔΔCt method, where the threshold cycle (ΔCt) = Ctarget gene - Ctβ-MG and ΔΔCt = 
ΔCtinduced – ΔCtreference. 
 
In vitro-induced GC B (iGB) Cell Culture 
Purified B cells (1x105) from naïve STAT3 control or cKO mice were cultured in RPMI-
1640 medium (Sigma, St. Louis, MO) (supplemented with 10% FBS, 5.5x10-5 M 2-ME, 
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100 units/ml-1 penicillin, and 100μg/mL-1 streptomycin (GIBCO, Waltham, MA)) on a 
12-well plate in the presence of CD40L and BAFF expressing feeder cells which had 
been irradiated with 120Gγ γ-rays (268). rIL-4 (1ng/mL, Peprotech, Rocky Hill, NJ) was 
added to the primary culture for 4 days. On day 4, cells were harvested, counted and used 
for secondary culture or analysis. For secondary culture, 2x105 cells from primary culture 
were re-plated on a new layer of irradiated CD40L feeder cells with 10ng/mL of rIL-21 
for 3 days.  
 
STAT3 ChIP-seq and ChIP-qPCR 
In vitro cultured GC B cells from STAT3 control and cKO mice were used for ChIP 
studies as described previously (329). In brief, cells were subjected to sonication using a 
sonicator (AFA Focused ultrasonicator S220) to obtain chromatin fragments of 100-500 
bp. Fragmented chromatin was incubated with STAT3 Ab (124H6, Cell Signaling 
Technology) or isotype control Ab and incubated for crosslinking with the beads 
(Dynabeads Protein G, Invitrogen). After crosslinking, crosslinks were reversed (65C 
for 12-16 h), and precipitated DNA was treated with Proteinase K and then purified 
(QIAquick PCR purification kit, Qiagen). The DNA libraries were prepared, and 
sequencing was performed by BGI (Beijing Genomics Institute). The number of clean 
reads is approximately 24 million. The ChIP-seq data have been deposited into NCBI 
GEO with the accession number (GSE120022). The primer sequences of Bcl3, Crtc2, 
Bach2, Stat4, and Stim1 for ChIP-qPCR analysis were listed in the Supplemental Table 1. 
For STAT3-binding motif analysis, the overlapping regions between the two differential 
peak lists were ranked by the differences between control and cKO reads, and peaks that 
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had fewer than 10 more reads were removed. The sequences were used as input into the 
MEME motif discovery software, using the oops model (one occurrence per sequence). 
 
OVA-Inhalation Asthma Model  
Control or cKO mice were immunized by i.p. injection of 25μg of OVA and 1mg Alum 
adjuvant, then boosted with the same treatment 14 days later. On day 21 post initial 
immunization, mice were anesthetized with isoflurane and challenged intranasally with 
250μg of OVA in 30μL PBS. Intranasal challenge was repeated on days 22 and 23, then 
mice were sacrificed on day 24. For microscopy, lobes of the lung were filled with and 
submerged in blocks of optimal cutting temperature (OCT) compound before rapid-
freezing at -140°C for storage. 
 
Immunofluorescence and Immunohistochemistry Staining 
Lung cryosections in OCT were sliced 9μm thick and fixed in acetone. For 
immunofluorescence, slices were blocked, stained with fluorescently labeled antibodies 
FITC-CD11b (Biolegend) and APC-CD193 (Biolegend) at 1:100 dilution overnight, then 
washed and stained with DAPI nuclear dye for 10 minutes before final wash and 
mounting. Images were acquired using a confocal microscope at 60x magnification 
(Nikon). For immunohistochemistry, slices were blocked overnight, stained with purified 
Gr-1 antibody at 1:50 dilution overnight. Slides were then washed and stained with 
secondary HRP-labeled antibody (Biolegend) at 1:1500 dilution for 25 minutes, washed 
and developed with peroxidase substrate (VECTOR Laboratories) for 10 minutes, then 
washed and counterstained with QS hematoxylin (VECTOR Laboratories) for 45 seconds 
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before final mounting. Images were acquired using Aperio Scanscope digital scanner at 
40x magnification. 
 
Statistical Analysis  
All quantitative data are shown as mean± s.e.m unless otherwise indicated. All samples 
were compared using two-tailed, unpaired Student’s T test. A P value less than 0.05 was 





STAT3 deficiency in B and T cell subsets disrupts the regulation of class switching 
in a Th2-type immunization 
STAT3 has previously been shown to play a role in the formation of the GC 
following immunization (330). Because B cell and Tfh cell interactions are crucial to the 
generation of an effective humoral immune response, we used a CD2 promoter driven 
Cre to investigate the effect of loss of STAT3 in these populations during a Th2 type 
immunization (331). At 7 days post immunization, a difference in antigen-specific IgE 
antibody titer could not be observed in the serum. However, levels of IgG and subclass 
IgG1 were significantly reduced at this time point. By 14 days after immunization, a 
marked increase in IgE was observed in CD2-cre;STAT3fl/fl mice. IgG and IgG1 also 
maintained their decreased titers to this period (Figure 40). 
Deletion of STAT3 on B and T cells caused impairment in germinal center formation. 
At day 14, STAT3 KO mice had significantly reduced overall GC frequency in the spleen 
compared to littermate controls (Figure 41, top). Within the GC population, there was 
also a shift in antibody class expression mirroring that seen in the peripheral blood. The 
amount of intracellular IgE expressing GCs was significantly increased in STAT3 
knockout mice. IgG1 expressing GCs appear to be slightly reduced although not 
statistically significant. Antibody-producing plasma cells were also affected by loss of 
STAT3. While the frequency of plasma cells in the spleen was not markedly altered, their 
expression of antibody class was (Figure 41, bottom). Knockout mice demonstrated a 




Due to this apparent disruption of the GC reaction, we opted to investigate the overall 
affinity of antibody produced in this model by immunizing mice with NP-CGG (332). 
Plates were coated with highly conjugated NP23-BSA which is able to bind low and high 
affinity anti-NP antibody, or a much lower ratio NP2-BSA which only binds high affinity 
antibody. An increased NP2/NP23 OD value ratio conveys a higher overall affinity of anti-
NP antibody produced (327). IgE antibody produced by STAT3 KO mice was 
significantly lower affinity than controls, indicating a clear defect in affinity maturation 
in the GC (Figure 42, left) Despite this decreased affinity, STAT3 KO mice still produced 
greater amounts of IgE as indicated by absolute absorbance. IgG1 affinity was also 
reduced in knockout mice (Fig 42, right). These data suggest a critical role for STAT3 in 






Figure 40: STAT3 regulates IgE antibody class switching in a Th2-type response. 
STAT3f/f control or CD2-Cre; STAT3f/f mice were immunized i.p. with 100μg OVA in 
Alum. Sera were collected at indicated time points and anti-OVA antibody levels of 
different classes and isotypes (IgE, IgG, and IgG1) were detected by ELISA. Data are 






Figure 41: STAT3 regulates GC and PC IgE class switching in a Th2-type response. 
STAT3f/f control or CD2-Cre; STAT3f/f mice were immunized i.p. with 100μg OVA in 
Alum. Spleens were harvested for FACS at day 14 post immunization. Cells were stained 
with mAbs B220, GL7, CD138, IgG
1
, and intracellular IgE. Representative dot plots and 
summarized results are shown from at least three independent experiments. Data are 





Figure 42: Loss of STAT3 leads to deceased antibody affinity in CD2-Cre driven 
STAT3 knockouts. Control and cKO mice were immunized with 50μg NP23-CGG in 
Alum via i.p. (A, B) Serum IgE (A) and IgG1 (B) were analyzed by ELISA with NP2-
BSA and NP23-BSA coated plates. Ratio of NP2 to NP23 absorbance (left) and absolute 
absorbance (right). Summarized results are from three independent experiments. Data are 





STAT3-dependent regulation of germinal center class switching is a B cell intrinsic 
effect 
Tfh and B cell interaction drives the formation and maintenance of the GC reaction. 
However, it is B cells that make up the majority of the structure and undergo a more 
drastic amount of change and regulation (333). Thus, we sought to determine if the 
STAT3 dependent regulation of GC class switching was an effect specifically intrinsic to 
the B cell population. We used a CD19-Cre driven knockout model to examine these 
effects. In order to better understand the kinetics of this effect, multiple time points were 
observed. As early as day 7, antigen specific IgG antibodies in the serum were decreased, 
while IgE was elevated as seen in the CD2-Cre model (Figure 43). At day 14 these 
effects were even more pronounced. Additional isotypes were analyzed for this time 
point; demonstrating a decrease in serum IgM and a decrease in IgG subclasses IgG1, 
IgG2a, and IgG2b. The affinity of day 14 antibody was also measured. Like the CD2-Cre 
model, both IgG and IgE anti-OVA antibody affinity was significantly reduced in 
knockout animals (Figure 44). 
Analogous to the previous experiment, the progression of the GC reaction was also 
investigated. The GC is typically fully formed by 7 days post immunization (333, 334). 
Predictably, we found a marked and significant decrease in GC B cells at this time 
(Figure 45, top). Within the GC, cells switched to the IgE class were markedly increased. 
Similar to the later time point, IgG1 expressing GC frequency was also decreased. The 
plasma cells population was less impacted at day 7, showing no change in number or 
IgG1 class switching. The IgE expressing subset, however, increased (Figure 45, bottom). 
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At 14 days post immunization these phenotypes became even more striking. The GC 
fraction was reduced in the absence of STAT3, while the IgE class subset was increased. 
The IgG1 subset was not altered at this time point (Figure 46, top). Plasma cells 
demonstrated the same marked increase in the IgE positive population but showed no 
other significant changes (Figure 46, bottom). 
Within the GC structure, actively maturing GC B cells cycle between two distinct 
compartments. The light zone of the GC contains antigen presenting cells which drive 
selection of high affinity B cells through competition for survival signals, while the dark 
zone is the site of B cell proliferation and somatic hypermutation that results from 
successful light zone selection (335). We suspected that dysregulation of the migration of 
GC B cells between these two paradigms may be involved in the irregular class switching 
in the STAT3 deficient model. Analysis of CD86 and CXCR4 expression within the GC 
population demonstrates a slight increase in the dark zone fraction over the light zone in 
CD19-cre;STAT3fl/fl mice (145) (Figure 47). 
Transcription factor Bcl6 is a master regulator for GC function and formation (336, 
337). Due to the decrease in GC formation in the STAT3 deficient mice, we sought to 
determine Bcl6 mRNA expression levels. Analysis showed lower Bcl6 expression in 
knockout mice compared to controls at day 14 (Figure 48). We also observed lower 
expression of Aicda, which is involved in somatic hypermutation and class-switch 
recombination in the GC (335).  Next, we examined expression of IRF4 and IRF5, which 
have been linked to class-switch regulation and B cell differentiation, respectively (338, 
339). These too were under-expressed in knockout mice. FOXO1, which is vital for the 
formation and maintenance of the dark zone stage of the germinal center reaction, was 
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also downregulated in these cells (335). Interestingly, expression of dark zone chemokine 
receptor CXCR4 was not altered despite the observed difference in GC dark zone and 
light zone distribution. These data suggest STAT3 plays a key upstream regulatory role 






Figure 43: STAT3 regulation of class switching is a B cell intrinsic effect. STAT3f/f 
control or CD19-Cre; STAT3f/f +p. with 100μg OVA in Alum. Sera were collected, and 
anti-OVA antibody levels of different classes and isotypes were detected by ELISA at 
given dilutions. All data are from day 14 post-immunization unless otherwise noted. 
Summarized results are from at least three independent experiments. Data are 






Figure 44: B cell STAT3 depletion alters antibody affinity Control and cKO mice were 
immunized with 50μg NP23-CGG in Alum via i.p. Serum was collected day 14 post 
immunization. IgE and IgG1 were analyzed by ELISA with NP2-BSA and NP23-BSA 
coated plates. Ratio of NP2 to NP23 absorbance (left) and absolute absorbance (right) are 
shown. Data are means±s.e.m. **P<0.01 (unpaired two-tailed Student’s t-test) *P<0.05; 





Figure 45: Loss of STAT3 in B cells alters early germinal center and plasma cell IgE 
class switching. STAT3f/f control or CD19-Cre; STAT3f/f mice were immunized i.p. 
with 100μg OVA in Alum. FACS analysis of splenocytes from day 7 post immunization 
mice. Cells were stained with mAbs B220, GL7, CD138, IgG1, and intracellular IgE. 
Representative dot plots and summarized results are from at least two independent 






Figure 46: STAT3 regulates germinal center and plasma cell IgE class switching in B 
cells. STAT3f/f control or CD19-Cre; STAT3f/f mice were immunized i.p. with 100μg OVA 
in Alum. FACS analysis of splenocytes from day 14 post immunization mice. Cells were 
stained with mAbs B220, GL7, CD138, IgG
1
, and intracellular IgE. Representative dot 
plots and summarized results are from at least three independent experiments. Data are 





Figure 47: STAT3 depletion alters germinal center light zone and dark zone 
distribution. STAT3f/f control or CD19-Cre; STAT3f/f mice were immunized i.p. with 
100μg OVA in Alum. FACS analysis of splenocytes from day 14 post immunization mice. 
FACS analysis of germinal center light zone and dark zone distribution. Cells were 





. Summarized results are from two independent experiments. Data are 





Figure 48: B cell deletion of STAT3 alters germinal center gene expression. GC gene 
expression of Bcl6, Aicda, IRF4, IRF5, FOXO1, and CXCR4 was measured using 
quantitative reverse transcriptase-PCR. GC cells were sorted from day 14 immunized WT 











































Depletion of STAT3 regulates germinal center class switching in vitro. 
Previous studies have successfully established an in vitro system to replicate the 
in vivo GC reaction (268). We aimed to determine if the STAT3 deficiency in B cells 
would replicate the previously observed phenotype under these conditions. Culture of 
purified STAT3 knockout B cells in the presence of IL-4 and CD40L- and BAFF-
expressing feeder cells produced fewer GC B-like cells at 96 hours, and induced less cell 
proliferation in general, but no changes in IgE expression (data not shown). Secondary 
culture with CD40L and IL-21 for 72 hours caused partial differentiation into plasma-like 
cells while maintaining a large portion of GC B-like cells. After this secondary 
differentiation, STAT3 knockout cultures maintained a reduced rate of overall expansion 
compared to controls (Figure 49). In addition, STAT3 knockout B cell culture continued 
to have reduced GC B-like frequency (Figure 50, top) However, these cells experienced 
greater IgE and fewer IgG1 class switching, mimicking the phenotype observed using in 
vivo Th2-driven immunization models. The plasma cell-like population also 
demonstrated similar results, displaying an increased overall frequency, increased IgE 
switching, and decreased IgG1 isotype subset (Figure 50, bottom). 
mRNA expression analyses were performed on the end-stage GC B-like and 
plasma cell-like populations to further confirm replication of the in vivo phenotype. GC 
B-like cells maintained significantly decreased expression of the germinal center genes 
Bcl6, Aicda, IRF4, IRF5, and FOXO1 (Figure 51, left). Unlike the in vivo GCs, CXCR4 
expression was decreased in these cells. Plasma-like cells also mimicked an in vivo 
expression pattern, with decreased Aicda, IRF4, and IRF5 (Figure 51, right). These data 
confirm the in vivo effect of STAT3 deficiency seen in mice and suggest that this effect is 
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Figure 49: STAT3 regulates IgE class switching of in-vitro generated germinal 
center B cells. Purified B cells from STAT3 control and cKO mice were cultured with 
CD40L and BAFF expressing feeder cells in the presence of IL-4 for 96 hours, followed 
by secondary culture with feeder cells and IL-21 for 72 hours. Total cell number from of 
secondary culture was evaluated by hemocytometer. Data are means±s.e.m. ***P<0.001 





Figure 50: STAT3 regulates IgE class switching of in-vitro generated germinal 
center B cells. Purified B cells from STAT3 control and cKO mice were cultured with 
CD40L and BAFF expressing feeder cells in the presence of IL-4 for 96 hours, followed 
by secondary culture with feeder cells and IL-21 for 72 hours. Cells were harvested and 
stained with mAbs CD138, GL7, IgG
1
, and intracellular IgE. FACS analysis of iGB (top) 
and iPC (bottom) IgG
1





 cells and CD138+ cells, as shown in the previous figure. Data are means±s.e.m. 
Summarized data are from at least three independent experiments. *P<0.05; **P<0.01; 




Figure 51: STAT3 regulates germinal center related genes in in vitro generated 
germinal center B cells. Gene expression of Bcl6, Aicda, IRF4, IRF5, FOXO1, and 
CXCR4 was measured using quantitative reverse transcriptase-PCR. Cells were sorted 
from day 7 cultured WT or cKO GC B-like (left) and plasma-like (right) cells. Data are 
means±s.e.m. Summarized data are from at least three independent experiments. 




Target genes of STAT3 in the GC B cells 
To further identify the direct or indirect target genes of STAT3 in the GC B cells, a 
STAT3 chromatin immunoprecipitation sequencing (ChIP-seq) study was carried out. In 
total, 3571 STAT3-binding sites were identified, most of them were located in introns or 
intergenic regions (Figure 52, left), suggesting that STAT3 may regulate gene expression 
through binding to distal regulatory elements. Gene Ontology (GO) analysis of 
differential peak related genes suggested that these genes are related to biological process 
such as immune regulation and metabolic process, cellular component, and molecular 
function (Figure 53, top). Ranking of genes associated with STAT3 based on the absolute 
number of sequencing tags, Bcl3 and Crtc2 were identified as the genes with the greater 
recruitment of STAT3 (Figure 52, right). In addition, Bach2, Stim1, and Stat4 had also 
binding site of STAT3 (data not shown). Interestingly, STAT3 itself was also found to be 
among the direct STAT3-regulated targets (data not shown).  
To validate results from ChIP-seq experiments, five STAT3 bound genes identified 
by ChIP-seq, including Bcl3, Crtc2, Bach2, Stat4, and Stim1 were selected. Bcl3 and 
Crtc2 showed strong binding to STAT3 while Bach2, Stat4 and Stim1 showed weak to no 
binding using iGB from STAT3 control and cKO mice (Figure 54). This was also 
confirmed using iGB from WT mice immunoprecipitated with STAT3 mAb or isotype 
control mAb (Figure 53, bottom). We also searched STAT3 binding motif using 
differentially expressed sequences between STAT3 control and cKO GC B cells. A de 
novo STAT3 binding motif was discovered (Figure 52, bottom), suggesting that target 
genes with the STAT3-binding motif may be involved in STAT3 regulated GC B cell 





Figure 52: STAT3 binding patterns in GC B cells. In vitro cultured GC B cells from 
STAT3 control and cKO mice were used for ChIP-seq study. (Left) The genomic 
distribution (%) of the identified STAT3-binding sites in GC B cells. (Right) Quantitative 
correlation of STAT3 at the Bcl3 and Crtc2 loci. (Bottom) De novo-derived STAT3 DNA 
binding motif. De novo motif was identified from the STAT3 ChIP-seq binding sites 





Figure 53: Gene Ontology (GO) analysis of differentially expressed peak related genes 
in STAT3 control and cKO GC B cells. Chromatins from wildtype GC B cells 
precipitated with STAT3 mAb or isotype control mAb were used for ChIP-qPCR 
analysis. Fold enrichment was calculated using isotype control as base level.  




Figure 54: STAT3-bound genes. in GC B cells.  Chromatins from STAT3 control and 
cKO mice were performed by ChIP-qPCR analysis for Bcl3, Crtc2, Bach2, Stat4, and 




STAT3 in B cells regulates lung inflammation during inhaled allergy reactions 
Increased production of IgE is a well-known hallmark of allergic disease. Asthma in 
particular has been strongly linked with the production of IgE antibodies specific to a 
wide range of allergens (340). We thus tested the response of CD19-cre;STAT3fl/fl mice 
in an induced asthma-like disease model. Briefly, mice were sensitized to OVA via 
immunization, then challenged intranasally thrice before sacrifice and analysis (Figure 
55, left). 
Consistent with our previous immunization models, CD19-cre;STAT3fl/fl mice 
continued to display a strong phenotype of increased serum antigen-specific IgE 
production as compared to control mice (Figure 55, right). Immunohistochemistry 
staining of the lungs revealed massive infiltration of Gr-1+ leukocytes, which mainly 
include neutrophils and eosinophils. In contrast, STAT3 proficient control mice had 
remarkably less infiltration, but were still increased compared to naïve mice (Figure 56). 
Furthermore, immunofluorescent staining of the lung tissue showed drastically more 
CD11b+CD193+ eosinophil infiltration in CD19-cre;STAT3fl/fl mice (Figure 57), 






Figure 55: Generation of an asthma-like model in STAT3 deficient mice. (Left) 
Schema of the inhalation model. STAT3f/f control or CD19-Cre; STAT3f/f mice were 
immunized i.p. with 25μg OVA/1mg Alum, then boosted 14 days later. On day 21 post 
immunization, mice were anaesthetized and challenged with 250μg OVA intranasally, 
followed by repeated challenges on days 22 and 23. Mice were sacrificed on day 24. 
(Right) Sera were collected at indicated time points and anti-OVA antibody levels of 
different classes were detected by ELISA. Data are means±s.e.m. Summarized data are 
from at least three independent experiments. *P<0.05; **P<0.01; ****P<0.0001 





Figure 56: STAT3 deficiency causes increased inflammation in an asthma-like 
model. Immunohistochemical staining of Gr-1 cells in the lungs of day 24 mice. Scale 
bar: 100μm. Images were acquired by Aperio ScanScope digital scanner. Lung section 






Figure 57: STAT3 deficiency causes increased eosinophil infiltration in an asthma-
like model. Immunofluorescence staining with FITC-CD11b, APC-CD193, and DAPI in 
the lungs of day 24 mice. Scale bar: 50μm. Images were obtained using Nikon ECLIPSE 





STAT3 is a central and essential signaling molecule for many different cell types. In 
this study, we have shown its function in B cells as a negative regulator of IgE class 
switching in the GC reaction. Previous work by other groups has demonstrated STAT6 
plays a critical role in the regulation of IgE germline expression in response to IL-4 
upstream signaling (341). Nonfunctional mutations in STAT3 have been strongly 
associated with incidence of AD-HIES. However, how STAT3 dysfunction leads to 
increased IgE production is unclear. Our group recently found that STAT3 deficiency 
leads to a defect in GC formation and IgG antibody production following hRBC 
immunization and Th1-type immune responses in mice (330, 342).  These data in 
combination with novel findings that IgG1 GC B cells are able to sequentially switch to 
IgE led us to investigate the impact of STAT3 on this pathway (343, 344). 
Stable interaction of Tfh cells with B cells is a pillar of the GC reaction. STAT3 has 
already been shown to regulate Tfh differentiation and GC participation, but the function 
of STAT3 in GC B cells is not well studied (345, 346). Using a CD2-Cre driven model to 
knock out STAT3 in both these cell types, we revealed a defect in GC formation and 
IgG1 production under Th2 driven immunization, mirroring prior studies using Th1 
reactions(330). However, a STAT3-knockout driven increase in production and class 
switching of IgE antibody has not been previously reported, suggesting this may be a Th2 
dependent phenomenon. 
Despite the importance of STAT3 in Tfh cell maintenance, use of a B cell specific 
knockout CD19-Cre model was able to replicate this phenotype, suggesting a B cell 
intrinsic defect. The reproduction of this phenomenon using B cell in vitro systems 
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further supports this conclusion. Interestingly, the frequency of antibody-producing 
plasma cells was unchanged following immunization despite the decrease in frequency of 
GC B cells, while the IgE expressing subpopulation increased. This suggests that effect 
of the STAT3 defect is limited to the GC reaction while the proliferation of the end-stage 
plasma cell product is not significantly affected. We also showed that loss of STAT3 
causes a disruption in the light zone and dark zone distribution of GC B cells. Migration 
between the light zone and dark zone of the GC is an essential part of the class switch and 
affinity maturation process, controlled by factors such as FOXO1, PI3K, and CXCR4 
(145, 347, 348). Indeed, FOXO1 expression was reduced in all STAT3 deficient GCs, 
though CXCR4 was unchanged in in vivo GC B cells. In other cell types, STAT3 has 
been shown to bind to the FOXO1 promoter and up-regulate expression, and thus may be 
directly controlling FOXO1 in B cells as well (349). Notably, we did demonstrate 
reduced IgE affinity in both CD2-Cre and CD19-Cre models, despite increased overall 
IgE production. This further implicates STAT3’s effect on not only GC formation, but 
the efficacy of the antibodies it generates as well. However, it remains unclear whether 
the disruption in IgG1/IgE class switching and affinity maturation is a direct consequence 
of the light zone/dark zone distribution defect, or another unrelated symptom of STAT3 
deficiency. 
Class switching occurs in mature B cells in response to antigen stimulation and co-
stimulatory signals. Excision of the DNA between the baseline mu promoter and 
downstream effector promoters causes expression of a new antibody class (350). IgE is 
unique in that and this process may happen either via a direct switch from IgM, or 
through sequential switch first to the IgG class followed by further switching to the 
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downstream IgE promoter (350, 351). Our findings suggest that STAT3 suppresses this 
sequential switching pathway, indicated by the associative drop in IgG1 and elevated IgE 
expression. This observation would suggest STAT3 may also be dampening the 
effectiveness of the IgE antibody response, as sequential switching produces higher 
affinity antibody than direct switching (327). However, we have found reduced IgE 
affinity in our knockout models, indicating a more complex role for STAT3 in IgE 
production.  
Direct regulation of both IgG1 and IgE class switching is reliant on Th2 cytokine 
signaling, most notably IL-4. STAT6 acts downstream of IL-4, binding to the Iε promoter 
and initiating IgE expression (352). Critical GC regulator Bcl6 has binding sites within 
the Iε promoter which overlap those of STAT6, acting as an antagonist (353, 354). 
STAT3 acts as an enhancer of Bcl6 expression and has confirmed binding sites within the 
Bcl6 promoter (355, 356). Indeed, GC Bcl6 expression was reduced in both our STAT3 
deficient in vivo and in vitro models. Therefore, STAT3 may be acting as a negative 
regulator of IgE class switching via enhancement of STAT6 competitor Bcl6. STAT3 
activation also causes increased expression of IRF4, which is required for GC formation 
(357, 358). We observed reduced IRF4 expression in knockout GCs and plasma cells. 
IRF4 downstream targets Aicda and IRF5 were reduced as well, which are vital in class 
switch regulation and B cell differentiation, respectively (338). These findings implicate 
STAT3 as a major upstream regulator of GC formation, function, and class switching. 
However, STAT3 ChIP-seq analysis reveals that none of these genes are identified as 
direct targets of STAT3. In addition, ID2 and NFIL3, two transcription factors critical for 
controlling IgE class switching do not have direct STAT3 binding sites, suggesting that 
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STAT3 may use an unidentified factor(s) to regulate IgE isotype switching in the GC B 
cells (325, 359). It is also possible that STAT3 targets of in vitro cultured GC-like B cells 
are different than in vivo primary GC B cells despite their similar phenotype.  Notably, 
Crtc2 has strong binding site on STAT3.  Crtc2 is a transcriptional coactivator for 
CREB1 (cAMP response element). Previous studies demonstrate that Crtc2 plays an 
important role in plasma cell differentiation and GC B cell malignancy (360, 361). 
Interestingly, Aicda, Myc, Bach2, TCF3, and TCL1 are among 136 direct Crtc2 target 
genes (361). It is possible that STAT3 may regulate GC differentiation and IgE isotype 
switching through Crtc2. 
In humans, STAT3 mutations have been strongly linked to incidence of AD-HIES, 
also known as Job’s syndrome (362, 363).  IgE is also known to mediate inflammatory 
symptoms in several allergic respiratory disorders (364). Additionally, STAT3 has been 
demonstrated to be involved in Th2 differentiation that may contribute to asthma disease 
(271). Despite high levels of IgE, AD-HIES patient incidence of allergy, anaphylaxis, and 
asthma condition is much less than that of other IgE related diseases (365). Inhibition of 
STAT3 in lung epithelial cells can even prevent lung inflammation in some asthma 
models, suggesting a protective role aginst allergy reaction in certain tissues (366).We 
demonstrated an increased eosinophil and inflammatory response in the lungs of CD19-
Cre driven knockout mice challenged in an asthma model, indicating B cell STAT3 is an 
effector of the allergic long response. However, this effect is likely ablated in many AD-
HIES patients by the protective loss of STAT3 in other tissues. It remains to be seen if 
other hyper-IgE disease hallmarks, such as susceptibility to recurrent pyogenic 
pneumonias, can also be caused by B cell STAT3 deficiency in mice (367). Impairment 
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of the IgG response magnitude and affinity due to defective STAT3 are likely significant 
contributing factors to these frequent infections. Mice expressing a nonfunctional form of 
STAT3 were previously shown to be more susceptible to C rodentium infection and 
inflammation of the colon, further supporting the role of STAT3 in protection from 
bacterial infection (368). 
To conclude, we have shown that STAT3 is able to control IgE class switching indirectly 
through regulation of vital upstream factors, which can alter the inflammatory response in 
the lungs. These newly discovered factors may serve a potential theraupetic targets for 
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